

(TO BE PUBLISHED IN THE GAZETTE OF INDIA PART-I SECTION-1)

Government of India (Bharat Sarkar)  
Ministry of Education (Siksha Mantralaya)  
Department of Higher Education (Uchcharat Siksha Vibhag)  
ICR Division

Shastri Bhawan, New Delhi-01,  
Dated the 27<sup>th</sup> July, 2023

**NOTIFICATION**

**No. 9-19/2000-U3(A)Pt.1:** Whereas, the Central Government is empowered under Section 3 of the University Grants Commission (UGC) Act, 1956 to declare, on the advice of the UGC, an Institution of higher learning as an Institution deemed to be University.

2. **And whereas,** in exercise of the powers conferred by Section 3 of the UGC Act, 1956, this Ministry, vide Notification No. 9-19/2000-U.3 dated 13.04.2006, on the advice of UGC, had declared KLE Academy of Higher Education & Research, Belgaum, Karnataka, comprising (i) Jawaharlal Nehru Medical College, Belgaum and (ii) KLE BK Institute of Dental Sciences, Belgaum, as an institution deemed to be University, for a period of five years.

3. **And whereas,** in exercise of the powers conferred by Section 3 of the UGC Act, 1956, the following institutions were brought under ambit of KLE Academy of Higher Education and Research, Belgaum, by this Ministry, vide Notification No.9-19/2000-U.3 dated 20.02.2009, subject to the conditions that all the terms & conditions of conferment of deemed to be university status to KLE Academy of Higher Education & Research, Belgaum shall remain unchanged:

- i. KLE Institute of Nursing Sciences, Belgaum;
- ii. KLE Institute of Physiotherapy, Belgaum;
- iii. KLE Shri B.M.K Ayurveda Mahavidyalaya, Belgaum;
- iv. KLE College of Pharmacy, Belgaum;
- v. KLE College of Pharmacy, Hubli;
- vi. KLE College of Pharmacy, Bangalore.

4. **And whereas,** in exercise of the powers conferred by Section 3 of the UGC Act 1956, the Central Government, vide Notification Nos. 9-19/2000-U3(A)Pt.1 dated 17.01.2017, 02.07.2018 & 06.05.2019, on the advice of UGC, extended the deemed to be University status of KLE Academy of Higher Education & Research, Belgaum upto 18.01.2021.

5. **And further whereas,** KLE Academy of Higher Education & Research, Belgaum made a request for extension /continuation of Institution Deemed to be University status. UGC considered the request of the Institution in its 570<sup>th</sup> meeting (Item No.2.05) held on 27.06.2023 as per the provisions of the UGC (**Institutions deemed to be Universities**) **Regulations, 2023** and advised for extension/continuation of Institution Deemed to be University status of KLE Academy of Higher Education & Research, Belgaum, Karnataka.

6. **Now, therefore,** in exercise of the powers conferred by Section 3 of the UGC Act, 1956, this Ministry, on the advice of UGC, hereby extends the deemed to be University

Resichin  
Jin

status of KLE Academy of Higher Education & Research, Belgaum, Karnataka from 19.01.2021 onwards.

7. All the other conditions mentioned in the earlier Notification(s) of this Ministry as well as the Rules / Regulations / directions of the Ministry, UGC and other Statutory Councils, issued from time to time, shall continue to be adhered by KLE Academy of Higher Education & Research, Belgaum, Karnataka.



(Ambrish Kumar Sharma)  
Under Secretary to the Government of India  
Tel: 23383934

The Manager,  
Government of India Press,  
Minto Road, New Delhi - 110002.

Copy forwarded to:-

1. The Secretary, University Grants Commission, Bahadurshah Zafar Marg, New Delhi.
2. The Vice-Chancellor, KLE Academy of Higher Education & Research, JNMC Campus, Nehru Nagar, Belgaum-590010.
3. The Principal Secretary to the Government of Karnataka, Department of Higher Education, Government of Karnataka Secretariat, MS Buildings, Dr. B. R. Ambedkar Veedi, Bangalore-560001.
4. The Member Secretary, All India Council for Technical Education (AICTE), Nelson Mandela Marg, Vasant Kunj, New Delhi-110070.
5. The Secretary Medical Council of India (MCI), Pocket-14, Sector-8, Dwarka Phase-I, New Delhi-110075.
6. The Secretary, Pharmacy Council of India (PCI), Post Box No.7020, Combined Councils' Building, Kotla Road, Aiwa-E-Ghalib Marg, New Delhi-110002.
7. The Secretary, Indian Nursing Council (INC), Bth Floor, NBCC Center, Plot No. 2, Community Center, Okhla Phasc-1, Pocket A, Okhla I, Okhla Industrial Area, Delhi.
8. The Under Secretary (ME-P.ID, Ministry of Health & Family Welfare, Nirman Bhawan, New Delhi-110011.
9. Press Information Bureau, Shastri Bhawan, New Delhi.
10. The Secretary General, Association of Indian Universities, AIU House, 16, Kotla Marg, New Delhi-2.
11. Web Master, Department of Higher Education, Shastri Bhawan, New Delhi. It is requested that CMIS Unit may kindly be instructed to display the Notification on the website (Home site) of the Department.
12. Guard file / Notification file.



(Ambrish Kumar Sharma)  
Under Secretary to the Government of India  
Tel: 23383934

**Dr. N.Gopukumar**  
**Joint Secretary**  
Ph. 011-23604219  
[www.ugc.ac.in](http://www.ugc.ac.in)  
email: [gopukumar.ugc@nic.in](mailto:gopukumar.ugc@nic.in)



विश्वविद्यालय अनुदान आयोग  
बहादुरशाह जफर मार्ग  
नई दिल्ली-110 002  
UNIVERSITY GRANTS COMMISSION  
BAHADURSHAH ZAFAR MARG  
NEW DELHI-110 002

**By Email**

No.F.1-1/2023 (CPP-I/DU)

October, 2023

**The Registrar,**  
**K.L.E. Academy of Higher Education and Research**  
**(Deemed to be University),**  
**J.N. Medical College Campus,**  
**Belgaum,**  
**Karnataka.**

06 OCT 2023


**Subject:** Proposals for inclusion in the list of Deemed to be Universities under Section 12 B of the UGC Act, 1956.

Sir,

This has reference to your application submitted for 12B status. The Commission in its 572<sup>nd</sup> meeting held on 20.09.2023 considered the application and decided to grant 12B status to K.L.E. Academy of Higher Education and Research (Deemed to be University), Belgaum, Karnataka. The status is subject to the condition that the financial assistance under all UGC schemes shall be limited to those relating to teachers and students only.

Accordingly, the K.L.E. Academy of Higher Education and Research (Deemed to be University) is included under section 12B of the UGC Act 1956 to be eligible for central assistance.

Yours faithfully,

  
(N.Gopukumar)



## राष्ट्रीय मूल्यांकन एवं प्रत्यायन परिषद

विश्वविद्यालय अनुदान आयोग का स्वायत्त संस्थान

### NATIONAL ASSESSMENT AND ACCREDITATION COUNCIL

An Autonomous Institution of the University Grants Commission

# Quality Profile

Name of the Institution : KLE Academy of Higher Education and Research


Place : JN Medical College Campus, Nehru Nagar, Belagavi, Karnataka

Criteria	Weightage ( $W_i$ )	Criterion-wise Weighted Grade Point (Cr WGP <sub>i</sub> )	Criterion-wise Grade Point Averages (Cr WGP <sub>i</sub> / $W_i$ )
I. Curricular Aspects	150	476	3.17
II. Teaching-Learning and Evaluation	200	680	3.40
III. Research, Innovations and Extension	250	857	3.43
IV. Infrastructure and Learning Resources	100	361	3.61
V. Student Support and Progression	100	318	3.18
VI. Governance, Leadership & Management	100	339	3.39
VII. Institutional Values and Best Practices	100	357	3.57
<b>Total</b>	$\sum_{i=1}^7 W_i = 1000$	$\sum_{i=1}^7 (Cr WGP_i) = 3388$	

$$\text{Institutional CGPA} = \frac{\sum_{i=1}^7 (Cr WGP_i)}{\sum_{i=1}^7 W_i} = \frac{3388}{1000} = \boxed{3.39}$$

Grade =  $\boxed{A^+}$

Date : February 22, 2022



S. C. Rame  
Director

- This certification is valid for a period of Five years with effect from February 22, 2022
- An institutional CGPA on four point scale in the range of 3.51 - 4.00 denotes A<sup>++</sup> grade, 3.26 - 3.50 denotes A<sup>+</sup> grade, 3.01 - 3.25 denotes A grade, 2.76 - 3.00 denotes B<sup>++</sup> grade, 2.51 - 2.75 denotes B<sup>+</sup> grade, 2.01 - 2.50 denotes B grade, 1.51 - 2.00 denotes C grade
- Scores rounded off to the nearest integer



**SUSTAINABLE INSTITUTIONS OF INDIA  
GREEN RANKINGS 2023**

*Certificate of Excellence*

IN PURSUIT OF EXCELLENCE TOWARDS PRACTICING  
SUSTAINABLE EDUCATION, THIS CERTIFICATE IS AWARDED TO

**KLE ACADEMY OF HIGHER EDUCATION AND  
RESEARCH**

Institutional Grade : **A++**

Institutional Band / Category : **Platinum**

**R**  
World Institutional  
**RANKING** ■■■



Executive President



सूचना का  
अधिकार  
RIGHT TO  
INFORMATION

दूरभाष/TEL : 26962819, 26567373  
(EPABX) : 26565694, 26562133  
: 26565687, 26562144  
: 26562134, 26562122  
फैक्स/FAX : 26960629, 26529745  
Website : <http://www.dsir.gov.in>



सत्यमेव जयते

भारत सरकार  
विज्ञान और प्रौद्योगिकी मंत्रालय  
वैज्ञानिक और औद्योगिक अनुसंधान विभाग  
टेक्नोलॉजी भवन, नया महरौली मार्ग,  
नई दिल्ली - 110016  
GOVERNMENT OF INDIA  
MINISTRY OF SCIENCE AND TECHNOLOGY  
Department of Scientific and Industrial Research  
Technology Bhavan, New Mehrauli Road,  
New Delhi - 110016



F.No. 14/934/2023-TU-V

Date: 4<sup>th</sup> December 2023

The Registrar  
KLE Academy of Higher Education and Research,  
JNMC Campus, Nehru Nagar,  
Belagavi – 590010, Karnataka

**Subject: Recognition of Scientific and Industrial Research Organisations (SIROs).**

Dear Sir,

This has reference to your application for recognition of **KLE Academy of Higher Education and Research, Belagavi, Karnataka** as a Scientific and Industrial Research Organisation (SIRO) by the Department of Scientific and Industrial Research under the Scheme on Recognition of Scientific and Industrial Research Organisations (SIROs), 1988.

2. This is to inform you that it has been decided to accord recognition to **KLE Academy of Higher Education and Research, Belagavi, Karnataka** from **06.11.2023 to 31.03.2026**. The recognition is subject to terms and conditions mentioned overleaf.

3. Receipt of this letter may kindly be acknowledged.

Yours faithfully,

  
(Dr. P.K. Dutta)  
Scientist - 'G'

## **TERMS AND CONDITIONS FOR RECOGNITION OF SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATIONS (SIROs)**

1. The organizations should acknowledge receipt of the recognition letter by stating that they will abide by the terms and conditions of recognition.
2. The recognition will entitle the SIRO to receive such administrative support from the DSIR, Ministry of Science & Technology as may be required on issue to promote or encourage scientific research activities.
3. SIROs recognized by DSIR are also deemed to be registered. A separate certificate of registration\*\* is issued along with the recognition letter. The recognition would be valid for the period specified in the recognition letter and application for renewal of recognition shall be submitted in the prescribed proforma at least 3 months before the expiry of the valid recognition. Failure to submit application in time may lead to automatic lapsing of the recognition & registration.  
*\*\*However, the certificate of registration is not issued to SIROs engaged in activities falling within the definition of 'hospital' as per notification No. 51/96-Cus. Dt. 23.07.1996 issued by the Department of Revenue.*
4. The recognition of DSIR does not amount to approval u/s 35(1)(ii)/(iii) of Income Tax Act, 1961.
5. The registration will entitle the SIROs to avail of custom duty exemption on purchase of equipment, instruments, spares thereof, consumables, etc. used for research and development subject to relevant Government policies in force from time to time. Custom duty exemption has to be separately dealt with the customs authorities. The SIROs should abide by the terms & conditions of the customs notifications issued/amended from time to time.
6. Separate books of accounts shall be maintained by the SIRO for research & development activities and the R&D expenditure, both capital and recurring should be reflected the Annual Report and Statement of Accounts of the Organization in separate schedules.
7. Disposal/sale of equipment and products/prototypes/intermediates, if any, emanating from the R&D/pilot plant, should be intimated to DSIR immediately. The realization, if any, from above or any services rendered etc. shall be shown in the R&D accounts of the organization as income of the SIRO in the audited accounts as well as annual report and should be used or reinvested for research activities only. In case of disposal/sale of R&D equipment, clearance from custom authorities will also be required in view of the applicable notifications under which the equipment was imported/purchased in India.
8. Accelerated depreciation allowance as per Rule 5(2) of Income Tax Rules 1962 will be available on investments on plant & machinery by any industrial unit which has made these investments for the purpose of commercialization of technology/know-how acquired from a SIRO recognition by DSIR.
9. Brief summary of the achievements of the organization shall be submitted to the DSIR every year. This should include details related to papers published, patents obtained and process developed, new products introduced, awards & prizes received, copy of Annual Report and Statement of Accounts of the organization etc. List of equipment, instruments, parts and consumables imported/purchased using the duty exemption should also be submitted to DSIR along with the Annual Report.
10. Any violation of the terms & conditions mentioned-above and / or provisions of taxation in force will make the organization liable to de-recognition.
11. The organization will also conform to such other conditions for recognition stipulated in the Guidelines or as may be specifically provided in the recognition letter.

\*\*\*\*\*





सूचना का  
अधिकार  
RIGHT TO  
INFORMATION

दूरभाष/TEL : 26962819, 26567373  
(EPABX) : 26565694, 26562133  
: 26565687, 26562144  
: 26562134, 26562122  
फैक्स/FAX : 26960629, 26529745  
Website : <http://www.dsir.gov.in>  
(आईएसओ 9001:2008 प्रमाणित विभाग)  
(AN ISO 9001:2008 CERTIFIED DEPARTMENT)



सत्यमेव जयते

भारत सरकार  
विज्ञान और प्रौद्योगिकी मंत्रालय  
वैज्ञानिक और औद्योगिक अनुसंधान विभाग  
टेक्नोलॉजी भवन, नया महरौली मार्ग,  
नई दिल्ली - 110016  
GOVERNMENT OF INDIA  
MINISTRY OF SCIENCE AND TECHNOLOGY  
Department of Scientific and Industrial Research  
Technology Bhavan, New Mehrauli Road,  
New Delhi - 110016



No. TU/V/RG-CDE (1249)/2023

Dated: 29-08-2023

To,  
The Registrar,  
K.L.E Academy of Higher Education and Research,  
J.N Medical College Campus,  
Nehru Nagar, Belagavi- 590010  
Karnataka

**Subject: Renewal of Registration of Public Funded Research Institutions or a University or an Indian Institute of Technology or Indian Institute of Science, Bangalore or a Regional Engg. College, Other than a hospital\*, for purposes of availing Customs Duty exemptions in terms of Notfn. No. 51/96-Customs dt. 23.07.1996, amended by notification 43/2017 dated 30.06.2017, further amended by Notification No: 42/2022- Customs dated 13.07.2022, as amended from time to time.**

**With Reference:** Your request dated 29.08.2022 on the above subject, this is the certificate of registration.

### CERTIFICATE OF REGISTRATION

This is to certify that **K.L.E Academy of Higher Education and Research, Belagavi, Karnataka**, other than Hospital\*, is registered with the Department of Scientific and Industrial Research (DSIR) for purposes of availing Customs Duty exemptions in terms of Notfn. No. 51/96- Customs dt. 23.07.1996, Notfn. No. 43/2017- Customs dt. 30.06.2017, further amended by Notification No. 42/2022- Customs dated 13.07.2022, as amended from time to time for research purposes only. This Registration is subject to terms & conditions mentioned overleaf.

This Registration is valid upto **31.03.2024**.

Please acknowledge the receipt.

Yours Faithfully,

(Surinder Pal Singh)

(Joint Secretary & Head PFRI)

\*Certificate of registration is not valid for activities falling within the definition of 'hospital' as per notification no. 51/96- Customs dated 23-07-1996 issued by the Department of Revenue. The institutions are cautioned to go through the notification before availing duty exemptions under this notification.





## FORUM FOR ETHICAL REVIEW COMMITTEES IN ASIA AND THE WESTERN PACIFIC

WHO-TDR Clinical Coordination and Training Center (CCTC), 1<sup>st</sup> Floor, Academic Affairs Building  
Advanced Research Center, Thammasat University (Rangsit Campus),  
99 Mu 18, Phaholyothin Road, Klongluang, Pathumthani 12121, Thailand  
Telefax: (+66) 025644440 ext 1800 | E-mail: [sidcerfercap@yahoo.com](mailto:sidcerfercap@yahoo.com) | Website: <http://www.fercap-sidcer.org>

---

22 November 2022

**DR. SUBARNA ROY**

Chairperson, Institutional Ethics Committee  
KLE Academy of Higher Education and Research  
Nehru Nagar, Belagavi, India

Dear Dr. Roy,

We are happy to inform you that the **Institutional Ethics Committee of KLE Academy of Higher Education and Research (IEC, KAHER)** surveyed last 11-15 July 2022 is cleared for renewal of recognition during the FERCAP Annual International Conference and General Assembly at Daegu, South Korea on 27-30 November 2022. We wish to invite you to attend this activity to receive the certificate of renewal of recognition for your institution.

FERCAP is a regional organization of researchers and ethics committee (EC) members initiated by the World Health Organization Special Programme for Research and Training in Tropical Diseases (WHO/TDR). We implement programs that improve the quality of ethical review in the Asia-Pacific region and we thank you for your support of this initiative.

As a FERCAP recognized institution, your EC is also an institutional member of FERCAP and its subcommittee, the Network of Asian Recognized Ethics Committees (NAREC). As FERCAP and NAREC institutional member, you are required to submit an annual report and pay the annual institutional membership fee of US\$300.

We hope that your institution will continue to be our partner towards capacity building of ECs in the Asia-Pacific region. We look forward to your active participation in FERCAP.

Sincerely yours,

**ARTHUR M. NAVARRO**  
FERCAP Program Manager



<p><b>Recipient Information</b></p> <p><b>1. Recipient Name</b>          THOMAS JEFFERSON UNIVERSITY          1020 WALNUT ST STE 1          PHILADELPHIA, PA 19107</p> <p><b>2. Congressional District of Recipient</b>          03</p> <p><b>3. Payment System Identifier (ID)</b>          1231352651A1</p> <p><b>4. Employer Identification Number (EIN)</b>          231352651</p> <p><b>5. Data Universal Numbering System (DUNS)</b>          053284659</p> <p><b>6. Recipient's Unique Entity Identifier</b>          R8JEVL4ULGB7</p> <p><b>7. Project Director or Principal Investigator</b>          RICHARD J DERMAN, MD          Associate Provost, Global Affairs          richard.derman@jefferson.edu          215/955-2153</p> <p><b>8. Authorized Official</b>          Jeanmarie Johnston</p>	<p><b>Federal Award Information</b></p> <p><b>11. Award Number</b>          2UG1HD076457-11</p> <p><b>12. Unique Federal Award Identification Number (FAIN)</b>          UG1HD076457</p> <p><b>13. Statutory Authority</b>          42 USC 241 31 USC 6305 42 CFR 52</p> <p><b>14. Federal Award Project Title</b>          TJU-JNMC Global Network for Women's and Children's Health Research Unit</p> <p><b>15. Assistance Listing Number</b>          93.865</p> <p><b>16. Assistance Listing Program Title</b>          Child Health and Human Development Extramural Research</p> <p><b>17. Award Action Type</b>          Competing Continuation</p> <p><b>18. Is the Award R&amp;D?</b>          Yes</p>																								
<p><b>Federal Agency Information</b></p> <p><b>9. Awarding Agency Contact Information</b>          Marianne Galczynski          Grants Management Specialist          EUNICE KENNEDY SHRIVER NATIONAL          INSTITUTE OF CHILD HEALTH &amp; HUMAN          DEVELOPMENT          marianne.galczynski@nih.gov          (240) 276-5588</p> <p><b>10. Program Official Contact Information</b>          Nahida Abdo Chakhtoura</p> <p>EUNICE KENNEDY SHRIVER NATIONAL          INSTITUTE OF CHILD HEALTH &amp; HUMAN          DEVELOPMENT          nahida.chakhtoura@nih.gov          (301) 435-6872</p>	<p><b>Summary Federal Award Financial Information</b></p> <table border="1"> <tr> <td colspan="2"><b>19. Budget Period Start Date 08/01/2023 – End Date 07/31/2024</b></td> </tr> <tr> <td><b>20. Total Amount of Federal Funds Obligated by this Action</b></td> <td style="text-align: right;">\$615,958</td> </tr> <tr> <td>    20 a. Direct Cost Amount</td> <td style="text-align: right;">\$548,574</td> </tr> <tr> <td>    20 b. Indirect Cost Amount</td> <td style="text-align: right;">\$67,384</td> </tr> <tr> <td><b>21. Authorized Carryover</b></td> <td></td> </tr> <tr> <td><b>22. Offset</b></td> <td></td> </tr> <tr> <td><b>23. Total Amount of Federal Funds Obligated this budget period</b></td> <td style="text-align: right;">\$615,958</td> </tr> <tr> <td><b>24. Total Approved Cost Sharing or Matching, where applicable</b></td> <td style="text-align: right;">\$0</td> </tr> <tr> <td><b>25. Total Federal and Non-Federal Approved this Budget Period</b></td> <td style="text-align: right;">\$615,958</td> </tr> <tr> <td colspan="2">-----</td> </tr> <tr> <td colspan="2"><b>26. Project Period Start Date 07/01/2013 – End Date 07/31/2030</b></td> </tr> <tr> <td><b>27. Total Amount of the Federal Award including Approved Cost Sharing or Matching this Project Period</b></td> <td style="text-align: right;">\$615,958</td> </tr> </table> <p><b>28. Authorized Treatment of Program Income</b>          Deduction</p> <p><b>29. Grants Management Officer - Signature</b>          Marianne Galczynski</p>	<b>19. Budget Period Start Date 08/01/2023 – End Date 07/31/2024</b>		<b>20. Total Amount of Federal Funds Obligated by this Action</b>	\$615,958	20 a. Direct Cost Amount	\$548,574	20 b. Indirect Cost Amount	\$67,384	<b>21. Authorized Carryover</b>		<b>22. Offset</b>		<b>23. Total Amount of Federal Funds Obligated this budget period</b>	\$615,958	<b>24. Total Approved Cost Sharing or Matching, where applicable</b>	\$0	<b>25. Total Federal and Non-Federal Approved this Budget Period</b>	\$615,958	-----		<b>26. Project Period Start Date 07/01/2013 – End Date 07/31/2030</b>		<b>27. Total Amount of the Federal Award including Approved Cost Sharing or Matching this Project Period</b>	\$615,958
<b>19. Budget Period Start Date 08/01/2023 – End Date 07/31/2024</b>																									
<b>20. Total Amount of Federal Funds Obligated by this Action</b>	\$615,958																								
20 a. Direct Cost Amount	\$548,574																								
20 b. Indirect Cost Amount	\$67,384																								
<b>21. Authorized Carryover</b>																									
<b>22. Offset</b>																									
<b>23. Total Amount of Federal Funds Obligated this budget period</b>	\$615,958																								
<b>24. Total Approved Cost Sharing or Matching, where applicable</b>	\$0																								
<b>25. Total Federal and Non-Federal Approved this Budget Period</b>	\$615,958																								
-----																									
<b>26. Project Period Start Date 07/01/2013 – End Date 07/31/2030</b>																									
<b>27. Total Amount of the Federal Award including Approved Cost Sharing or Matching this Project Period</b>	\$615,958																								
<p><b>30. Remarks</b></p> <p>Acceptance of this award, including the "Terms and Conditions," is acknowledged by the recipient when funds are drawn down or otherwise requested from the grant payment system.</p>																									



Cooperative Agreement  
Department of Health and Human Services  
National Institutes of Health

Notice of Award



EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT

---

**SECTION I – AWARD DATA – 2UG1HD076457-11**

**Principal Investigator(s):**

RICHARD J DERMAN, MD

**Award e-mailed to:** resadmin@jefferson.edu

Dear Authorized Official:

The National Institutes of Health hereby awards a grant in the amount of \$615,958 (see “Award Calculation” in Section I and “Terms and Conditions” in Section III) to THOMAS JEFFERSON UNIVERSITY in support of the above referenced project. This award is pursuant to the authority of 42 USC 241 31 USC 6305 42 CFR 52 and is subject to the requirements of this statute and regulation and of other referenced, incorporated or attached terms and conditions.

Acceptance of this award, including the "Terms and Conditions," is acknowledged by the recipient when funds are drawn down or otherwise requested from the grant payment system.

Each publication, press release, or other document about research supported by an NIH award must include an acknowledgment of NIH award support and a disclaimer such as “Research reported in this publication was supported by the Eunice Kennedy Shriver National Institute Of Child Health & Human Development of the National Institutes of Health under Award Number UG1HD076457. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.” Prior to issuing a press release concerning the outcome of this research, please notify the NIH awarding IC in advance to allow for coordination.

Award recipients must promote objectivity in research by establishing standards that provide a reasonable expectation that the design, conduct and reporting of research funded under NIH awards will be free from bias resulting from an Investigator’s Financial Conflict of Interest (FCOI), in accordance with the 2011 revised regulation at 42 CFR Part 50 Subpart F. The Institution shall submit all FCOI reports to the NIH through the eRA Commons FCOI Module. The regulation does not apply to Phase I Small Business Innovative Research (SBIR) and Small Business Technology Transfer (STTR) awards. Consult the NIH website <http://grants.nih.gov/grants/policy/coi/> for a link to the regulation and additional important information.

If you have any questions about this award, please direct questions to the Federal Agency contacts.

Sincerely yours,

Marianne Galczynski  
Grants Management Officer  
EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT

Additional information follows

---

---

**Cumulative Award Calculations for this Budget Period (U.S. Dollars)**

Salaries and Wages	\$78,180
Fringe Benefits	\$8,148
Personnel Costs (Subtotal)	\$86,328
Travel	\$9,000
Subawards/Consortium/Contractual Costs	\$453,246
Federal Direct Costs	\$548,574
Federal F&A Costs	\$67,384
Approved Budget	\$615,958
Total Amount of Federal Funds Authorized (Federal Share)	\$615,958
<b>TOTAL FEDERAL AWARD AMOUNT</b>	<b>\$615,958</b>
<b>AMOUNT OF THIS ACTION (FEDERAL SHARE)</b>	<b>\$615,958</b>

SUMMARY TOTALS FOR ALL YEARS (for this Document Number)		
YR	THIS AWARD	CUMULATIVE TOTALS
11	\$615,958	\$615,958
12	\$601,958	\$601,958
13	\$601,958	\$601,958
14	\$601,958	\$601,958
15	\$601,958	\$601,958
16	\$601,958	\$601,958
17	\$601,958	\$601,958

Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project

**Fiscal Information:**

**Payment System Identifier:** 1231352651A1  
**Document Number:** UHD076457D  
**PMS Account Type:** P (Subaccount)  
**Fiscal Year:** 2023

IC	CAN	2023	2024	2025	2026	2027	2028	2029
HD	8014707	\$615,958	\$601,958	\$601,958	\$601,958	\$601,958	\$601,958	\$601,958

Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project

**NIH Administrative Data:**

**PCC:** PPB -NC / **OC:** 41027 / **Released:** Galczynski, Marianne 07/21/2023  
**Award Processed:** 08/01/2023 12:32:00 AM

---

**SECTION II – PAYMENT/HOTLINE INFORMATION – 2UG1HD076457-11**

For payment and HHS Office of Inspector General Hotline information, see the NIH Home Page at <http://grants.nih.gov/grants/policy/awardconditions.htm>

---

**SECTION III – STANDARD TERMS AND CONDITIONS – 2UG1HD076457-11**



This award is based on the application submitted to, and as approved by, NIH on the above-titled project and is subject to the terms and conditions incorporated either directly or by reference in the following:

- a. The grant program legislation and program regulation cited in this Notice of Award.
- b. Conditions on activities and expenditure of funds in other statutory requirements, such as those included in appropriations acts.
- c. 45 CFR Part 75.
- d. National Policy Requirements and all other requirements described in the NIH Grants Policy Statement, including addenda in effect as of the beginning date of the budget period.
- e. Federal Award Performance Goals: As required by the periodic report in the RPPR or in the final progress report when applicable.
- f. This award notice, INCLUDING THE TERMS AND CONDITIONS CITED BELOW.

(See NIH Home Page at <http://grants.nih.gov/grants/policy/awardconditions.htm> for certain references cited above.)

**Research and Development (R&D):** All awards issued by the National Institutes of Health (NIH) meet the definition of “Research and Development” at 45 CFR Part§ 75.2. As such, auditees should identify NIH awards as part of the R&D cluster on the Schedule of Expenditures of Federal Awards (SEFA). The auditor should test NIH awards for compliance as instructed in Part V, Clusters of Programs. NIH recognizes that some awards may have another classification for purposes of indirect costs. The auditor is not required to report the disconnect (i.e., the award is classified as R&D for Federal Audit Requirement purposes but non-research for indirect cost rate purposes), unless the auditee is charging indirect costs at a rate other than the rate(s) specified in the award document(s).

Carry over of an unobligated balance into the next budget period requires Grants Management Officer prior approval.

This grant is excluded from Streamlined Noncompeting Award Procedures (SNAP).

This award is subject to the requirements of 2 CFR Part 25 for institutions to obtain a unique entity identifier (UEI) and maintain an active registration in the System for Award Management (SAM). Should a consortium/subaward be issued under this award, a UEI requirement must be included. See <http://grants.nih.gov/grants/policy/awardconditions.htm> for the full NIH award term implementing this requirement and other additional information.

This award has been assigned the Federal Award Identification Number (FAIN) UG1HD076457. Recipients must document the assigned FAIN on each consortium/subaward issued under this award.

Based on the project period start date of this project, this award is likely subject to the Transparency Act subaward and executive compensation reporting requirement of 2 CFR Part 170. There are conditions that may exclude this award; see <http://grants.nih.gov/grants/policy/awardconditions.htm> for additional award applicability information.

In accordance with P.L. 110-161, compliance with the NIH Public Access Policy is now mandatory. For more information, see NOT-OD-08-033 and the Public Access website: <http://publicaccess.nih.gov/>.

This award provides support for one or more clinical trials. By law (Title VIII, Section 801 of [Public Law 110-85](#)), the “responsible party” must register “applicable clinical trials” on the [ClinicalTrials.gov Protocol Registration System Information Website](#). NIH encourages registration of all trials whether required under the law or not. For more information, see [http://grants.nih.gov/ClinicalTrials\\_fdaaa/](http://grants.nih.gov/ClinicalTrials_fdaaa/)

Recipients must administer the project in compliance with federal civil rights laws that prohibit discrimination on the basis of race, color, national origin, disability, age, and comply with applicable conscience protections. The recipient will comply with applicable laws that prohibit discrimination on the

basis of sex, which includes discrimination on the basis of gender identity, sexual orientation, and pregnancy. Compliance with these laws requires taking reasonable steps to provide meaningful access to persons with limited English proficiency and providing programs that are accessible to and usable by persons with disabilities. The HHS Office for Civil Rights provides guidance on complying with civil rights laws enforced by HHS. See <https://www.hhs.gov/civil-rights/for-providers/provider-obligations/index.html> and <https://www.hhs.gov/>.

- Recipients of FFA must ensure that their programs are accessible to persons with limited English proficiency. For guidance on meeting the legal obligation to take reasonable steps to ensure meaningful access to programs or activities by limited English proficient individuals, see <https://www.hhs.gov/civil-rights/for-individuals/special-topics/limited-english-proficiency/fact-sheet-guidance/index.html> and <https://www.lep.gov>.
- For information on an institution's specific legal obligations for serving qualified individuals with disabilities, including providing program access, reasonable modifications, and to provide effective communication, see <http://www.hhs.gov/ocr/civilrights/understanding/disability/index.html>.
- HHS funded health and education programs must be administered in an environment free of sexual harassment; see <https://www.hhs.gov/civil-rights/for-individuals/sex-discrimination/index.html>. For information about NIH's commitment to supporting a safe and respectful work environment, who to contact with questions or concerns, and what NIH's expectations are for institutions and the individuals supported on NIH-funded awards, please see <https://grants.nih.gov/grants/policy/harassment.htm>.
- For guidance on administering programs in compliance with applicable federal religious nondiscrimination laws and applicable federal conscience protection and associated anti-discrimination laws, see <https://www.hhs.gov/conscience/conscience-protections/index.html> and <https://www.hhs.gov/conscience/religious-freedom/index.html>.

In accordance with the regulatory requirements provided at 45 CFR 75.113 and Appendix XII to 45 CFR Part 75, recipients that have currently active Federal grants, cooperative agreements, and procurement contracts with cumulative total value greater than \$10,000,000 must report and maintain information in the System for Award Management (SAM) about civil, criminal, and administrative proceedings in connection with the award or performance of a Federal award that reached final disposition within the most recent five-year period. The recipient must also make semiannual disclosures regarding such proceedings. Proceedings information will be made publicly available in the designated integrity and performance system (currently the Federal Awardee Performance and Integrity Information System (FAPIIS)). Full reporting requirements and procedures are found in Appendix XII to 45 CFR Part 75. This term does not apply to NIH fellowships.

**Treatment of Program Income:**

Deduction

---

**SECTION IV – HD SPECIFIC AWARD CONDITIONS – 2UG1HD076457-11**

Clinical Trial Indicator: Yes

This award supports one or more NIH-defined Clinical Trials. See the NIH Grants Policy Statement Section 1.2 for NIH definition of Clinical Trial.

**Foreign Clearance**

**RESTRICTION:** No funds may be expended, and no activities may be conducted at **JNMC, KLE Academy of Higher Education and Research** in **INDIA** until all NIH administrative requirements have been met. These activities and funds will remain restricted until a revised Notice of Award has been issued rescinding this restriction.

Failure to comply with the above requirement may result in suspension and/or termination of this award, withholding of support, audit disallowances, and/or other appropriate action.

## **Dissemination Plan**

**RESTRICTION:** In absence of a plan for the dissemination of NIH-funded clinical trials information, all funds for this award are restricted [with the exception of those costs associated with supporting currently enrolled patients].

No funds may be drawn down from the payment system and no obligations may be made against Federal funds, [except for those associated with patient care for currently enrolled patients] prior to NICHD notification to the recipient via a revised Notice of Award that the identified issues have been resolved and this restriction removed.

## **Cooperative Agreement**

This award is issued as a cooperative agreement, a financial assistance mechanism in which substantial NIH scientific and/or programmatic involvement is anticipated in the performance of the activity.

This award is subject to the terms and conditions of award as set forth in **NOFO NUMBER [RFA-HD-23-008](#)**, "NICHD Global Network for Women's and Children's Health Research: Research Units (UG1 Clinical Trial Optional)," posted August 03, 2022, which are hereby incorporated by reference as special terms and conditions of award. See the [NIH Funding](#) site for more information.

These special terms and conditions of award are in addition to, and not in lieu of, otherwise applicable OMB administrative guidelines; Federal Regulations including HHS Grant Administration Regulations at 45 CFR Part 75; other HHS regulations; and the [NIH Grants Policy Statement](#) (rev. 12/22).

## **Project Scientist Contact Information:**

**Project Scientist:** Marion Koso-Thomas, MD  
**Email:** [kosomari@mail.nih.gov](mailto:kosomari@mail.nih.gov) **Phone:** (301) 435 - 6873

## **Foreign Component**

This award includes foreign component at the following site(s): **JNMC, KLE Academy of Higher Education and Research in INDIA**

## **Human Subjects - Delayed Onset**

**RESTRICTION:** This award is issued with the knowledge that subjects may be involved within the period of support, but definite plans were not set forth in the application as per 45 CFR 46.118. No human subjects may be involved in any project supported by this award until all requirements for human subjects' research as identified in the PHS398/SF424 instructions have been provided to and approved by NICHD.

For all competing applications or new protocols, the NICHD expects investigators for ALL NICHD Clinical Trials to abide by the requirements stated in NIH Guide Notice [NOT-HD-20-036](#) "NICHD Data Safety Monitoring Guidelines for Extramural Clinical Trials and Clinical Research". All NICHD applications which include Clinical Trials must include a Data Safety Monitoring Plan. All NIH-sponsored multi-site clinical trials, NIH-defined Phase III clinical trials and some single site clinical trials that pose potential risk to participants require Data and Safety Monitoring Board (DSMB) oversight. Applicants are expected to establish an independent, external DSMB when required by this policy.

For all competing applications or new protocols, the NICHD expects investigators for ALL human subject research to abide by the requirements stated in NIH Guide Notice [NOT-HD-20-035](#) "NICHD Serious Adverse Event, Unanticipated Problem, and Serious Adverse Event Reporting Guidance".

## **SPREADSHEET SUMMARY**

**AWARD NUMBER:** 2UG1HD076457-11

**INSTITUTION:** THOMAS JEFFERSON UNIVERSITY

Budget	Year 11	Year 12	Year 13	Year 14	Year 15	Year 16	Year 17
Salaries and Wages	\$78,180	\$78,180	\$78,180	\$78,180	\$78,180	\$78,180	\$78,180
Fringe Benefits	\$8,148	\$8,148	\$8,148	\$8,148	\$8,148	\$8,148	\$8,148
Personnel Costs (Subtotal)	\$86,328	\$86,328	\$86,328	\$86,328	\$86,328	\$86,328	\$86,328
Travel	\$9,000	\$9,000	\$9,000	\$9,000	\$9,000	\$9,000	\$9,000
Subawards/Consortium/Contractual Costs	\$453,246	\$453,246	\$453,246	\$453,246	\$453,246	\$453,246	\$453,246
TOTAL FEDERAL DC	\$548,574	\$548,574	\$548,574	\$548,574	\$548,574	\$548,574	\$548,574
TOTAL FEDERAL F&A	\$67,384	\$53,384	\$53,384	\$53,384	\$53,384	\$53,384	\$53,384
TOTAL COST	\$615,958	\$601,958	\$601,958	\$601,958	\$601,958	\$601,958	\$601,958

Facilities and Administrative Costs	Year 11	Year 12	Year 13	Year 14	Year 15	Year 16	Year 17
F&A Cost Rate 1	56%	56%	56%	56%	56%	56%	56%
F&A Cost Base 1	\$120,328	\$95,328	\$95,328	\$95,328	\$95,328	\$95,328	\$95,328
F&A Costs 1	\$67,384	\$53,384	\$53,384	\$53,384	\$53,384	\$53,384	\$53,384



**Australian Government****National Health and Medical Research Council**

In reply, please quote: **NHMRC 2023 Centres of Research Excellence Application 2024658**

Professor Caroline Homer

caroline.homer@burnet.edu.au

**\*\*\*\*\* UNDER EMBARGO AND PROVIDED IN CONFIDENCE \*\*\*\*\***

This advice and document/s referred to below are provided under strict [embargo](#) and as such, on an in confidence basis. **The document/s and the information are not to be made public at this time by institutions or recipients.** NHMRC will notify your Administering Institution when your outcome is no longer under embargo.

\*\*\*\*\*

Dear Professor Homer

**Application ID: 2024658**

**Grant Opportunity: 2023 Centres of Research Excellence**

**Application Title: ARPAN - Accelerating Research and Progress in maternal And Newborn health: A Centre for Research Excellence to improve maternal and newborn health in the post-COVID-19 pandemic era**

I am pleased to advise that the Minister for Health and Aged Care has approved your application (2024658) for National Health and Medical Research Council (NHMRC) 2023 Centres of Research Excellence commencing in 2023.

This letter provides you with important information about the offer of Funding made to Burnet Institute for this application.

#### **Assessment Details**

Where available<sup>1</sup>, information about the assessment of your application is provided in a separate Application Assessment Summary.

#### **Accepting this offer**

The offer of Funding for your Application is made under NHMRC's Funding Agreement (the Funding Agreement) between the Australian Government and your Administering Institution. Your Administering Institution is responsible for informing you about the requirements of the Funding Agreement (including its Schedules), the Direct Research Costs guidelines and other applicable policies<sup>2</sup>.

Your Administering Institution has until 15/10/2023 to certify that the information required prior to payment being made (see below) has been entered into NHMRC's Grant Management System, and to advise NHMRC of its acceptance of the offer. If the offer is not accepted by this date it may lapse. If you wish to discuss this offer of Funding, or have any queries, please contact your Research Administration Officer (RAO).

<sup>1</sup> An Application Assessment Summary is not available for applications to grant opportunities where NHMRC does not perform the peer review.

<sup>2</sup> Funding Agreement, Direct Research Costs Guidelines and other policies are available on the webpage at: (<https://nhmrc.gov.au/funding/manage-your-funding/funding-agreement>).

**Information required prior to payment being made**

Where applicable, and except where otherwise indicated, NHMRC will temporarily withhold some or all of the Funding under subclause 15.2.a of the Funding Agreement with your Administering Institution until Specified Personnel with outstanding obligations from previous NHMRC grants, including submission of a Final Report, have met those obligations.

In some circumstances, CIAs may need to provide additional ethics information. This information must be entered into NHMRC's Grant Management System by the CIA and certified by the RAO. Should you have any questions concerning the provision of such information, please speak to your RAO.

If you need to seek approval to defer the start date of this grant, please refer to the [Grantee Variations](#) webpage or speak with your RAO.

**Funding**

As set out in the Schedule to the Funding Agreement, the 2023 Centres of Research Excellence 2024658, has been awarded \$2,500,000.00. Where applicable, this budget has been assessed by the peer review panel as sufficient to complete the aims and objectives of the research proposal stated in the application for funding. Any conditions relevant to receiving the Funding are set out in the Schedule to the Funding Agreement and, where applicable, the associated Funding Policy. All expenditure must be in accordance with the requirements of the Funding Agreement.

**Participation in NHMRC Peer Review**

NHMRC relies on the ongoing participation of the research community to ensure that every application receives expert peer review. NHMRC is grateful for this contribution which is acknowledged on its website's peer review honour roll.

To ensure that applications for future rounds are appropriately assessed, all Specified Personnel working on NHMRC Funded Research Activities are reminded that they may be requested to make themselves available to contribute to the peer review process, in accordance with clause 23.1 of the Funding Agreement.

Accordingly, we ask that you ensure your CV/Profile information is up to date in Sapphire to assist in the identification of appropriate peer reviewers.

Yours sincerely

[Authorised for electronic transmission]

Alan Singh  
Executive Director  
Research Translation Branch

**Cover Page (1 page)**

**ARPAN - Accelerating Research and Progress in maternal And Newborn health: A Centre for Research Excellence to improve maternal and newborn health in the post-COVID-19 era**

**Chief Investigators**

CIA Prof Caroline Homer	Burnet Institute	Australia 
CIB A/Prof Joshua Vogel	Burnet Institute	Australia 
CIC Prof Pisake Lumbiganon	Khon Kaen University	Thailand 
CID Prof Shivaprasad Goudar	KLE Academy of Higher Education and Research, Jawaharlal Nehru Medical College	India 
CIE Prof William Pomat	PNG Institute for Medical Research	Papua New Guinea 
CIF A/Prof Meghan Bohren	University of Melbourne	Australia 
CIG Dr Lisa Vallely	Kirby Institute, UNSW and PNG Institute for Medical Research	Australia  PNG 
CIH Prof Kirsten Black	University of Sydney	Australia 
CII Prof Adrienne Gordon	University of Sydney, Stillbirth Centre for Research Excellence	Australia 
CIJ Dr Susannah Leisher	International Stillbirth Alliance	USA 

**Associate Investigators**

AI Ms Catherine Breen Kamkong	United Nations Population Fund (Bangkok)	Asia-Pacific region
AI Dr Titilola Duro-Aina	United Nations Population Fund (Fiji)	Pacific region
AI Ms Anayda Portela	World Health Organization	Switzerland 
AI A/Prof Porjai Pattanittum	Khon Kaen University	Thailand 
AI A/Prof Kiattisak Kongwattanakul	Khon Kaen University	Thailand 
AI Prof Yeshita Pujar	KLE Academy of Higher Education and Research, Jawaharlal Nehru Medical College	India 
AI Prof Manjunath Somannavar	KLE Academy of Higher Education and Research, Jawaharlal Nehru Medical College	India 
AI Dr John Bolnga	Modillon Hospital, Madang province and the PNG Institute for Medical Research	PNG 
AI Dr Michelle Scoullar	Burnet Institute	Australia 
AI Dr Billie Bradford	Stillbirth Centre for Research Excellence, International Stillbirth Alliance.	Australia and New Zealand  



World Health  
Organization

REGIONAL OFFICE FOR South-East Asia

**OFFICE ADDRESS:**

**PERMANENT:** WORLD HEALTH HOUSE, INDRAPRASTHA ESTATE, MAHATMA GANDHI ROAD, NEW DELHI-110 002, INDIA, [WWW.SEARO.WHO.INT](http://www.searo.who.int)

**TEMPORARY:** METROPOLITAN HOTEL OFFICE BLOCK, BANGLA SAHIB ROAD, GOLE MARKET, SECTOR 4, NEW DELHI-110 001, INDIA

ANNEX – RED FORT CAPITAL PARSVNATH TOWER 1, BHAI VIR SINGH MARG, GOLE MARKET, SECTOR 4, NEW DELHI-110 001, INDIA  
TEL: 91-11-4304 0200 /0161, FAX: 91-11-2336 8355

In reply please refer to:

Dr Niranjana Mahantashetti  
Director  
Women's and Children's Health Research  
Unit, Jawaharlal Nehru College  
KLE Academy of Higher Education and  
Research  
JNMC Campus, Nehru Nagar  
Belagavi, Karnataka

25 October 2023

Dear Dr Mahantashetti,

**Subject:** Redesignation of Women's and Children's Health Research Unit, Jawahar Lal Nehru Medical College as a WHO Collaborating Centre for Research in Maternal and Perinatal Health (WHO-CC IND 156)

I am pleased to inform you that the World Health Organization has designated the Women's and Children's Health Research Unit, Jawaharlal Nehru Medical College, KLE Academy of Higher Education and Research, Belagavi (JNMC Research Unit) as a WHO Collaborating Centre for Research in Maternal and Perinatal Health (WHO-CC IND 156).

As previously agreed, Dr Shivaprasad Goudar will act as Head of the Centre. Should there be any change in the future, I would be grateful if you would inform WHO without delay.

The agreed terms of reference and workplan of the Centre are attached. We wish to emphasize that institutions designated as WHO Collaborating Centres are expected to implement the agreed workplan in a timely manner and to the highest possible standard of quality. Any issue that may affect the implementation of the agreed workplan should be brought to the attention of the WHO responsible officer Dr Mariana Widmer at [widerm@who.int](mailto:widerm@who.int)

For information on administrative matters, please visit the WHO website <https://www.who.int/southeastasia/about/partnerships/collaborating-centres>.

Cont'd...2/-

cc: The Secretary, Ministry of Health and Family Welfare, Government of India, Nirman Bhawan, New Delhi  
The Joint Secretary (IH Division), Ministry of Health and Family Welfare, Government of India, Nirman Bhawan, New Delhi  
The WHO Representative to India, Nirman Bhawan, New Delhi

Dr Niranjana Mahantashetti  
Director  
Women's and Children's Health Research  
Unit, Jawaharlal Nehru College  
KLE Academy of Higher Education and  
Research  
JNMC Campus, Nehru Nagar  
Belagavi, Karnataka

25 October 2023

---

Finally, please note that institutions designated as WHO Collaborating Centres must complete a short online progress report form once a year. On the anniversary of the designation date, details will be sent to the email address of the Head of the Centre specified in the designation form.

The designation as a WHO Collaborating Centre will be effective for a period of 4 years of redesignation, as from **14 September 2023**, and will automatically end on **14 September 2027**, unless redesignation has been approved by WHO before that date. During the period of designation, either party may revoke the designation at any time by giving three months advance notice in writing.

I look forward to our successful collaboration.

Yours sincerely,



Dr Poonam Khetrpal Singh  
Regional Director

Encl: As stated





**icmr**  
INDIAN COUNCIL OF  
MEDICAL RESEARCH  
Serving the nation since 1911

## ICMR- Collaborating Centre of Excellence (ICMR-CCoE)

The Indian Council of Medical Research has designated the **Jawaharlal Nehru Medical College, Belagavi** led by **Dr Shivaprasad Sadashivappa Goudar** as ICMR- Collaborating Centre of Excellence (ICMR-CCoE) in recognition of the commendable achievements in biomedical research

*Rajiv Bahl*

DR. RAJIV BAHL

Director General, Indian Council of Medical Research  
4 November, 2023



National Accreditation Board for  
Testing and Calibration Laboratories

**CERTIFICATE OF ACCREDITATION**

**HIV TESTING LABORATORY, DEPARTMENT  
OF MICROBIOLOGY, J N MEDICAL COLLEGE**

has been assessed and accredited in accordance with the standard

**ISO 15189:2012**

**"Medical laboratories - Requirements for quality and  
competence"**

for its facilities at

JAWAHARLAL NEHRU-MEDICAL COLLEGE, KLE UNIVERSITY, NEHRU NAGAR, BELGAUM,  
KARNATAKA, INDIA

in the field of

**Medical Testing**

Certificate Number: MC-2286

Issue Date: 16/11/2021

Valid Until:

15/11/2023

This certificate remains valid for the Scope of Accreditation as specified in the annexure subject to continued satisfactory compliance to the above standard & the relevant requirements of NABL.  
(To see the scope of accreditation of this laboratory, you may also visit NABL website [www.nabl-india.org](http://www.nabl-india.org))

Name of Legal Identity : KLE University

Signed for and on behalf of NABL



N. Venkateswaran  
Chief Executive Officer



# National Accreditation Board for Testing and Calibration Laboratories

## SCOPE OF ACCREDITATION

Laboratory Name :

HIV TESTING LABORATORY, DEPARTMENT OF MICROBIOLOGY, J N MEDICAL COLLEGE, JAWAHARLAL NEHRU MEDICAL COLLEGE, KLE UNIVERSITY, NEHRU NAGAR, BELGAUM, KARNATAKA, INDIA

Accreditation Standard

ISO 15189:2012

Certificate Number

MC-2286

Page No

1 of 1

Validity

16/11/2021 to 15/11/2023

Last Amended on

-

S.No	Discipline / Group	Materials or Products tested	Component, parameter or characteristic tested / Specific Test Performed / Tests or type of tests performed	Test Method Specification against which tests are performed and / or the techniques / equipment used
Permanent Facility				
1	MICROBIOLOGY & INFECTIOUS DISEASE SEROLOGY	Serum	HIV 1&2 antibody detection by rapid test	Dot immunoassay
2	MICROBIOLOGY & INFECTIOUS DISEASE SEROLOGY	Serum	HIV 1&2 antibody detection by rapid test	Immunochromatography
3	MICROBIOLOGY & INFECTIOUS DISEASE SEROLOGY	Serum	HIV 1&2 antibody detection by rapid test	Immunoconcentration assay
4	MOLECULAR TESTING	Nasopharyngeal swab/ Oropharyngeal swab in VTM /ET secretion/BAL in VTM	SARS COV-2 RNA Qualitative	Real Time RT PCR (open system)





# भारतीय आयुर्विज्ञान परिषद् MEDICAL COUNCIL OF INDIA

75  
YEARS

Platinum Jubilee  
(1933 - 2008)

पॉकेट - 14, सेक्टर - 8, द्वारका, नई दिल्ली - 110 077  
Pocket - 14, Sector - 8, Dwarka, New Delhi - 110 077


No. MCI-Academics/2014

118863

Date:

9.7.14

✓ Dr. A. S. Godhi,  
Dean & Principal  
Jawaharlal Nehru Medical College,  
Nehru Nagar, Belgaum - 590 010  
Karnataka  
Ph. - 0831 - 2471350, 2471701, 2470101 (Direct)  
Res: - 0831 - 2470102, 2430063  
Fax: 0831-2470759; M: 09844121868  
E-mail: [principal@jnmc.edu](mailto:principal@jnmc.edu), [drashokgodhi@jnmc.edu](mailto:drashokgodhi@jnmc.edu)




Sub: letter No. MDC/Dome/584 dated 18-05-2014 on Nodal Centre for FDP programme-  
reg

Sir,


I have been directed to inform you that Medical Council of India has been pleased to upgrade the Regional Centre in MET at your Institution to Nodal Centre in MET and conduct Advance Course in Medical Education.

The Academic Cell has already sent you a letter requesting you to nominate a Convener & Co-Convener to conduct the Advance Course. Your reply, which has not been received so far, may be expedited. The Centre would continue to conduct the Basic Course Workshop in MET.

Yours faithfully,

  
(Dr. Davinder Kumar)  
Joint secretary, MCI

Dr. Sumita &  
Dr. Padmaja } to peruse the letter  
and act accordingly  
draft of the reply to be put up



भारतीय आयुर्विज्ञान परिषद्  
**MEDICAL COUNCIL OF INDIA**

पॉकेट - 14, सेक्टर - 8, द्वारका, नई दिल्ली - 110 077  
Pocket - 14, Sector - 8, Dwarka, New Delhi - 110 077


478  
**75**  
YEARS

Platinum Jubilee  
(1933 - 2008)

No.MCI-Academics/2014/ 1/8024

Date: 4-7-14

1. Dr. S. M. Bhatti  
Principal, Christian Medical College,  
Brown Road,  
Ludhiana-141008  
Punjab  
Phone: 0161-2610856, 5010819; Fax: 0161-5010819  
M: 9646900336  
E-mail: [smbhatti\\_99@yahoo.com](mailto:smbhatti_99@yahoo.com); [principal.medical@cmcludhiana.in](mailto:principal.medical@cmcludhiana.in)  
[principal\\_cmcl@hotmail.com](mailto:principal_cmcl@hotmail.com)
2. Dr Sandeep Srivastava  
Professor, Orthopaedics and Dean  
Jawaharlal Nehru Medical College,  
Sawangi (Meghe)Wardha 442004,  
Maharashtra  
Mobile: 09765404014 / 09422802397  
Off. 07152-287701 to 287706 Ext.202; Fax: 07152-287714  
M:09765404068  
Email: [drsandeepshrivastava@hotmail.com](mailto:drsandeepshrivastava@hotmail.com); [drsandeepshrivastava@yahoo.com](mailto:drsandeepshrivastava@yahoo.com)
3. Dr Shubhangi Parkar  
Dean -in-Charge  
Professor and Head, Psychiatry,  
Seth GSMC and KEM Hospital, Parel  
Email: [deangsmc@kem.edu](mailto:deangsmc@kem.edu); [pshubhangi@gmail.com](mailto:pshubhangi@gmail.com)  
Mumbai-400012, Maharashtra  
Off. 022-24131419, 24136051; Fax: 020-24142503  
Mobile: 09820703191
4. Dr. S. Anandan  
Dean, Sri Ramachandra Medical College  
& Research Institute,  
No. 1, Ramachandra Nagar, Porur, Chennai-600 116 Tamil Nadu  
PH. 044 - 24765625, Fax: 044 - 24767008  
Mobile: 09444150373  
E-mail: [deansrmc@hotmail.com](mailto:deansrmc@hotmail.com); [anandan\\_subbu@yahoo.co.in](mailto:anandan_subbu@yahoo.co.in)
5. Dr K Srinivasan  
Dean,  
St. John's Medical College,  
Johnnagar, Sarjapura Road,  
Bangalore - 560 034 Karnataka  
PH. - 080 - 22065030; Fax: 080 - 25530737  
Ph: 0091 80 49466006 Fax : 0091 80 25530737  
Email : [dean.sjmc@stjohns.in](mailto:dean.sjmc@stjohns.in); [srinivas@stjohns.in](mailto:srinivas@stjohns.in)
6. Dr. Utpala Kharod  
Dean, Pramukhsami Medical College,  
Karamsad, Gujarat - 388325  
Distt. Anand, Gujarat  
Ph.: 02692-223661, 222420, 02692-222420, Fax: 02692-223660/ 223466  
M: 09825318749  
E-mail: [psmc@charutarhealth.org](mailto:psmc@charutarhealth.org); [utpala\\_kharod@hotmail.com](mailto:utpala_kharod@hotmail.com)







# भारतीय आयुर्विज्ञान परिषद् MEDICAL COUNCIL OF INDIA

पॉकेट - 14, सेक्टर - 8, द्वारका, नई दिल्ली - 110 077  
Pocket - 14, Sector - 8, Dwarka, New Delhi - 110 077

479  
75  
YEARS

Platinum Jubilee  
(1933 - 2008)

7  
Dr. A. S. Godhi,  
Dean & Principal  
Jawaharlal Nehru Medical College,  
Nehru Nagar, Belgaum - 590 010  
Karnataka  
Ph. - 0831 - 2471350, 2471701, 2470101 (Direct)  
Res: - 0831 - 2470102, 2430063  
Fax: 0831-2470759  
M: 09844121868  
E-mail: [principal@jnmc.edu](mailto:principal@jnmc.edu), [drashokgodhi@jnmc.edu](mailto:drashokgodhi@jnmc.edu)

8. Dr Alfred Job Daniel  
Principal, Christian Medical College  
Bagayam, Vellore-632002  
Tamil Nadu,  
Ph: 0416-228 4201  
Fax: 0416-2262788  
Mobile: 09677770171  
Email - [princi@cmcvellore.ac.in](mailto:princi@cmcvellore.ac.in)
- 9 Dr. Pankaj R Patel  
Dean /Principal  
Smt. N.H.L.Municipal Medical College,  
Ellis Bridge, Ahmedabad-380006  
Off. 079-26578452/26576275/26575388; Fax: 079-26579282  
Mobile:09327426851  
E-mail: [pankajpatel@gmail.com](mailto:pankajpatel@gmail.com); [deannhlmmc@yahoo.com](mailto:deannhlmmc@yahoo.com);  
[deannhlmmc@yahoo.co.in](mailto:deannhlmmc@yahoo.co.in)
10. Dr. A. Remla Beebi  
Principal, Government Medical College  
Gandhinagar, Kottayam - 686008  
Ph: 0481-2597284  
Fax no. 0481- 2597284  
Mobile: 099463 58827  
fax: 0481-2597284  
E mail: [medicalcollegekottayam@gmail.com](mailto:medicalcollegekottayam@gmail.com)


**Sub:- Nomination of Convenor for conduct of Advance Course in Medical Education by MCI Nodal Centres in MET-reg.**

Madam/Sir,

The Medical Council of India is initiating conduct of Advance Course in Medical Education by the Nodal Centres given from Sr. No. 1 to 8 immediately and subsequently by Nodal Centres given from Sr. No. 9 -10. The Council has laid down norms for conduct of Advance Course in the attached document. As per this document, the Resource Faculty in each Nodal Centre to conduct the Advance Course should fulfill the following requirements:

**a. Minimal requirement and Criteria for Resource faculty to conduct advanced course**

- Each Nodal Centre should have at least 5 faculty who fit into one of the following criteria:
  - ✓ Degree in medical education
  - ✓ Diploma in medical education



# भारतीय आयुर्विज्ञान परिषद् MEDICAL COUNCIL OF INDIA

पॉकेट - 14, सेक्टर - 8, द्वारका, नई दिल्ली - 110 077  
Pocket - 14, Sector - 8, Dwarka, New Delhi - 110 077

15  
YEARS

Platinum Jubilee  
(1933 - 2008)

- ✓ FAIMER ( Foundation for Advancement of International Medical Education and Research) Fellowship
- ✓ Advanced course in medical education (project based longitudinal course)


During the initial transitory period of 3 years the deficient requirement of not more than 20% could be met with by the faculty fulfilling the following criteria:

- An education lead who has developed and implemented a national or state level educational programme

At each contact session of the Nodal Centre, MCI will depute a National Consultant.

In view of the above, you are requested to nominate Convener and Co-Convener for the Nodal Centre at your Institution for conducting Advance Course in MET, fulfilling the above required criteria, forthwith for launching of Nodal Centres for Advance Course.

Yours faithfully,

  
(Dr. Davinder Kumar)  
Joint Secretary

Encl: as above

**Copy for information:**

- 1 The President, Medical Council of India, New Delhi
- 2 Dr. Ved Prakash Mishra, Chairman, Academic Committee, MCI. Plot No.3, Neera Apartment, 1<sup>st</sup> Floor. Opp NIT Telecom Garden, Ramakrishna Nagar, Nagpur - 440 025.



# National Accreditation Board for Hospitals & Healthcare Providers

(Constituent Board of Quality Council of India)

## CERTIFICATION

**KLES Dr. Prabhakar Kore Hospital  
& Medical Research Centre**  
P. B. Road, Nehru Nagar  
Belgaum - 590010, Karnataka

has been assessed and found to comply with NABH  
Entry Level -Hospital requirements.  
This certificate is valid for the Scope as specified in the  
annexure subject to continued compliance with the  
Entry Level requirements.

Date of first Certification: December 20, 2018

Date of Previous Cycle

December 20, 2020 to December 19, 2022

Valid from : December 20, 2022


Valid thru : December 19, 2024



Certificate No.  
PEH-2018-0667

**Dr. Atul Mohan Kochhar**  
Chief Executive Officer

National Accreditation Board for Hospitals & Healthcare Providers, 5th Floor, ITPI Building, 4A, Ring Road, IP Estate, New Delhi 110 002, India  
Phone: +91-11-42600600, Fax: +91-11-2332 3415 • Email: helpdesk@nabh.co • Website: www.nabh.co



SI No. 014120



NABH as an organisation is ISQua Accredited



# National Accreditation Board for Hospitals & Healthcare Providers

(Constituent Board of Quality Council of India)

## CERTIFICATE OF ACCREDITATION

**Institutional Ethics Committee of KLE University**

**KLES Dr. Prabhakar Kore Hospital and MRC**

Nehru Nagar, JNMC Campus  
Belagavi - 590010, Karnataka

has been assessed and found to comply with NABH  
Accreditation Standards for Ethics Committee (E.C)  
under clinical trial program.

This certificate is valid subject to continued compliance  
with NABH Accreditation Requirements.

Date of first accreditation: January 21, 2018

Valid from : January 21, 2021

Valid thru : January 20, 2024



EC-CT-2018-0015

Certificate No.  
EC-CT-2018-0015

**Dr. Atul Mohan Kochhar**  
Chief Executive Officer

National Accreditation Board for Hospitals & Healthcare Providers, 5th Floor, ITPI Building, 4A, Ring Road, IP Estate, New Delhi 110 002, India  
Phone: +91-11-42600600, Fax: +91-11-2332 3415 • Email: helpdesk@nabh.co • Website: www.nabh.co



SI No. **002963**

\*002963\*

**NABH**

NABH as an organisation is ISQua Accredited





National Accreditation Board for  
Testing and Calibration Laboratories

**CERTIFICATE OF ACCREDITATION**

**KLES DR. PRABHAKAR KORE HOSPITAL AND MRC HI  
TECH LABORATORY**

has been assessed and accredited in accordance with the standard

**ISO 15189:2012**

**"Medical laboratories - Requirements for quality and  
competence"**

for its facilities at

NEHRUNAGAR, BELGAUM, KARNATAKA, INDIA

in the field of

**Medical Testing**

Certificate Number: MC-2352

Issue Date: 07/04/2022

Valid Until:

06/04/2024

This certificate remains valid for the Scope of Accreditation as specified in the annexure subject to continued satisfactory compliance to the above standard & the relevant requirements of NABL.  
(To see the scope of accreditation of this laboratory, you may also visit NABL website [www.nabl-india.org](http://www.nabl-india.org))

Name of Legal Identity : KLES Prabhakar Kore Hospital and Medical Research Centre

Signed for and on behalf of NABL



N. Venkateswaran  
Chief Executive Officer



## MEMORANDUM OF UNDERSTANDING

### Hospital Based Cancer Registries in India

National Cancer Registry Programme

ICMR-National Centre for Disease Informatics and Research, Bengaluru

The broad and overall objective of ICMR-National Centre for Disease Informatics and Research (ICMR-NCDIR), Bengaluru is to sustain and develop a national research data-base on cancer, diabetes, CVD, stroke, other NCDs and their risk factors through recent advances in electronic information technology with a national collaborative network, so as to undertake etiological, epidemiological, clinical and disease control research in these areas.

The National Cancer Registry Programme (NCRP) was initiated in 1981 by the ICMR, and is presently coordinated at ICMR-NCDIR, Bengaluru. It operates through a network of Population Based Cancer Registries (PBCRs) and Hospital Based Cancer Registries (HBCRs) across different parts of the country. The data collected enables to estimate cancer incidence, mortality, trends, burden, clinical management, outcome and survival. The information aids efforts towards cancer prevention and control in the country.

This Hospital Based Cancer Registry is being implemented by ICMR- NCDIR, Bengaluru at KLE'S DR PRABHAKAR KORE HOSPITAL & MRC BELAGAVI with the following aim / objectives.

1. Profile and patterns of cancer in patients attending the hospital/health facilities
2. Describe the diagnostic, clinical, treatment and outcome parameters
3. Contribute to the respective PBCRs in India under ICMR-NCDIR-NCRP

The basic methodology for the project "Hospital Based Cancer Registries in India" envisages capturing core patient information on demography, clinical details, treatment and outcome of all cancers reported/registered at all departments/units/sections who are involved in cancer diagnosis/treatment/care in the hospital.

Agreement for co-operation in the performance of work on "Hospital Based Cancer Registries in India" through ICMR-NCDIR, Bengaluru between Dr. Prashant Mathur, Director, ICMR-National Centre for Disease Informatics and Research, Bengaluru, hereinafter called Principal Investigator (PI) and DR KUMAR VINCHURKAR hereinafter called Principal Investigator of Participating Centre (C-PI).

The project sanction is up to March 2027 and it is effective from 1<sup>st</sup> April 2023. The funds will be released on installment basis based on quality of data submission and overall performance. The C-PI is responsible for the following:

1. Collection, collation and transmission of data of all malignant neoplasms reported/diagnosed/treated from the above centre from 1<sup>st</sup> January 2023 onwards.
2. Follow the terms and conditions (as specified in **Annexure I**) are necessary for uniformity and successful execution of the study.
3. Managing funds provided for the said purpose as per guidance and rules applicable.
4. Submission of duly signed utilization certificate on a regular basis.

In consideration of the above, an annual budget of up to ₹ **3,15,000/-** (In Rupees Three Lakh and Fifteen Thousand only ) per year is provided for the financial year 2023-24, and will be released in installments after receiving duly completed MoU and other codal formalities.

The undersigned parties hereby agree and conclude the present agreement:

Signature:

\_\_\_\_\_  
Name, title & Institution:  
Dr. Prashant Mathur  
Principal Investigator & Director  
ICMR-NCDIR, Bengaluru  
Email ID: [director-nkdir@icmr.gov.in](mailto:director-nkdir@icmr.gov.in)  
Date:

Signature:

\_\_\_\_\_  
Principal Investigator (C-PI)

Name: Dr Kumar Vinchurkar  
Designation:  
Consultant Surgical  
Oncology  
Mobile: 8277538780  
Email: vkumar\_007@yahoo.com  
Date: 11/05/2023

\_\_\_\_\_  
Head of the institution

Name: **Dr. M. V. Jali,**  
MD., FRCP (LONDON), D.L.R.  
Designation: **Medical Director and CEO**  
**KLES Cancer Hospital,**  
Mobile: **Professor & Chief Diabetologist,**  
Email: **KMC Reg. No. 16554**  
**KLES Dr. Prabhakar Kore Hospital & MRC**  
**KAHER'S J. N. Medical College,**  
Full Postal address: **Belagavi - 590010 INDIA**

Institutional website:

Date:

**drmvjali@gmail.com**  
↳ **medicaldirector@klehospital.org**  
**medicaldirector@klescancerhospital.org**

## ANNEXURE-I

### Terms and Conditions

#### Roles and Responsibilities:

##### A. Principal Investigator (PI), ICMR-NCDIR

1. Deploy standard protocol, tools and methods of National Cancer Registry Programme (NCRP) for collection of data at HBCRs. This includes provision of Core forms for abstraction of cases, procedure manuals and technical support to the participating center or study tools, as per needs of the study.
2. Access to the online software along with secure login credentials to the C-PI.
3. To organize periodic training, re-training of registry staff. This will employ physical onsite programs as well as online electronic methods
4. Monitor the quality of data being collected, transmitted to ICMR-NCDIR, completeness and clarifications
5. The cancer data collected through this collaboration will be used to augment the NCRP database.
6. ICMR- NCDIR does not accept any responsibility for persons hired for the activity by the participating centre and thus will have no legal liability relating to the implementation of this MoU.

##### B. Principal Investigator of the participating centre (C-PI)

1. C-PI will be nominated by the respective Head of Institution. All other Co-PIs will be identified by the C-PI as relevant (i.e., clinicians from surgical/radiation/medical oncology departments and a pathologist) to the implementation of the project with the approval of Head of the Institution.
2. C-PI will have overall responsibility for the execution of the project in the participating centre as per guidelines. This basically includes collection and collation of data of all malignant neoplasms reported/diagnosed/treated in the participating centre from the 1<sup>st</sup> January 2023, with specific attention to capture of complete and correct residential address, including patient identification details, exact anatomical site of cancer, stage and treatment. HBCR should cover the cases from various departments/units (surgery, radiation, medical oncology, pediatrics, general medicine/surgery, obstetrics and gynaecology, ophthalmology and other departments) from the entire institution whenever any case of cancer is diagnosed or managed to cover complete details. Data collection has to be done in the prescribed format (HBCR coreform) as per guidelines provided in the procedure manual. The same data should be entered into the online software provided by ICMR-NCDIR and transmitted preferably daily to ICMR-NCDIR.
3. The C-PI will be the main corresponding / contact person for all matters including utilization of funds and be the overall in-charge of the project Hospital Based Cancer Registry in India.
4. C-PI should have Co-Principal Investigators (Co-PI) from all the oncology and cancer related departments. If for any reason the C-PI leaves, an eligible clinician/Co-PI with the concurrence of the Head of the Institution should be nominated and a request for approval of ICMR-NCDIR should be sent well in advance along with detailed Biodata and letter of acceptance for the position and responsibility.
5. Based on local set-up the C-PI /Co-PIs could also identify junior staff members as Faculty-in-charge. This person(s) along with the senior most staff employed under the project would be responsible for the day to day working of the project. This day to day working includes ensuring:
  - i) Completion of core proforma for "Hospital Based Cancer Registry in India" and regular data transmission.



- ii) Maintain the quality of data during abstraction and transmission.
  - iii) Ensure that the hired manpower is acquainted with the methodology of data collection and abstraction through interim in-house reviews.
  - iv) Internal meetings with all the investigators and concerned staff should be conducted periodically.
  - v) Assist in order to provide any clarifications sought by ICMR-NCDIR;
6. Facilitate the Principal Investigator/representative(s) during their visits for monitoring, supervision and quality assurance of the data collected.
  7. The C-PI and Co-PIs along with the concerned staff should strictly adhere to participate in the meetings along with suitable representative who will also participate in workshops / training programmes and present the progress of work.
  8. As ICMR-NCDIR is providing the funds for the project Hospital Based Cancer Registries in India, the primary data of HBCR belongs both to your centre and to ICMR-NCDIR. Therefore, the C-PI should take approval from ICMR-NCDIR before providing/sharing the primary data with any third party / any agency. The ICMR-NCDIR policy on data processing and disclosure shall be followed as applicable from time to time.
  9. The space and basic equipment, furniture and other assistance required for the smooth working of the project shall be provided by the host institution. No assets should be procured from the project fund.
  10. Hiring of manpower for the purpose of project as per the rules and regulations of the participating centre and should take the overall responsibility.

**C. Accounts:**

1. Grant-in-aid: General, Lump sum grants would be released.
  - i) Submission of Utilization Certificate along with Receipts and Payments Accounts after completion of the financial year (duly certified and signed by C-PI and Accounts Officer / Head of the Institution to be submitted).
  - ii) Adjustment of closing balance of previous year as shown in Utilization Certificate.
2. Head of the Institution / C-PI will have the liberty of allocation of the funds for functioning of registry and its requirements such as hiring of manpower, training, workshop, contingencies etc. as such C-PIs may get work done in an effective manner. No person should be hired on very long term basis continuously.
3. The funds provided should be spent for the purpose for which it has been sanctioned and should not exceed the allocated budget. Any deviation in budget utilization needs prior approval from ICMR-NCDIR, Bengaluru
4. Funds would be provided to your institutional bank account or specific account dedicated for this project and details of records of expenditure incurred shall be maintained. The accounts will be subjected to audit by the authorized auditors/accounts officer of the centre.
5. Bank interest accrued in a financial year should not be utilized by the centre and should be refunded to ICMR-NCDIR.
6. The grant released by ICMR-NCDIR shall be refunded as per unspent amount available at the participating centre if and when ICMR-NCDIR or grantee concerned discontinues mid-way or does not follow the terms and conditions laid down and approved.

7. The C-PI must keep track of all circulars/ Notices/ Letters sent by ICMR-NCDIR.

**D. Core and Patient Information Form:**

1. The project core forms will be printed and provided to the respective participating centre by ICMR-NCDIR.
2. A hard copy of the core form should be completed (and updated) for all malignant cases reported in the respective participating centre.
3. The filled hard copy of the core form shall be preserved for a minimum of 5 years from the date of termination of the project.

**E. Data Transmission:**

1. Transmission of data on each patient has to be done regularly through the website <https://www.ncdirindia.org>. The login credentials to access the online software will be provided by ICMR-NCDIR.
2. The centre has to place a request for replenishment of HBCR core forms at least one month in advance through the portal.
3. The core identifying and diagnostic information/ Treatment details has to be transmitted within two weeks of data collection.
4. Methods for coordination with other departments, verification of quality errors and data entry should be developed by each participating centre.
5. ICMR-NCDIR will monitor the completeness and quality of data transmitted periodically.
6. Poor quality of data will not be accepted for publication in the periodic reports of the NCRP.

**F. Quality of data:**

HBCR data which is submitted undergoes following processing steps at ICMR-NCDIR:

1. ICMR NCDIR assess the coverage of the data from the respective hospital. Data abstraction should be done from all departments including pathology, surgical oncology, radiation oncology, medical oncology and any other departments where cancer is diagnosed and treated. If there is a lack of coverage, the registry will be informed to ascertain missing cases. Once the data is complete, the following steps are taken to make it complete, free from errors as per standards and international norms.
2. Quality Control –
  - a. Data should be complete in all aspects, especially the treatment and follow up details.
  - b. Registries can perform checks on the data transmitted through the HBCR software. NCDIR shall also perform checks on the data to evaluate the quality of the submitted data. The generation of error tables is followed by the dispatch of erroneous data to respective registries for inputs/corrections. The corrections are made in the HBCR software by the respective registries.
  - c. Duplicates are identified and shared with the registry for concurrence and subsequently the elimination is done by ICMR -NCDIR.
  - d. Data is further evaluated for consistency checks and if the coverage and quality of data is found to be satisfactory, data of the centre is finalized and will be used for analysis and report preparation.

**G. Data Access:**

- a. Each centre is provided access to download its own raw data for quality control (above Point no. 2. a,b,c ) at any time for purposes of data monitoring, and any further analysis. It is to be noted that this data has not completed the Quality control steps and therefore is not final data. The C-PI is responsible for the access of data at this stage, and its further use.
- b. Data that has completed all steps of QC (2.a to d) is final and will be included in the analysis for reports and publications prepared by ICMR-NCDIR.
- c. The finalized data will be also available for access to each participating centre for further use as deemed fit.

**H. Report of Work Done:**

1. The grant is being sanctioned on the condition that reports on the progress of work done on the project will be submitted by the participating centre to the ICMR-NCDIR, as and when called for as per format.
2. Timely release of grants necessitates timely submission of data to ICMR-NCDIR. The deadlines for submission of data have to be adhered.

**I. Data use and Publication:**

1. The HBCR can share information with another HBCR under NCRP only based on specific request from another HBCR under information to ICMR-NCDIR.
2. HBCR data shall be used by ICMR-NCDIR to strengthen the information in case diagnosis/treatment/follow up/outcome in any PBCR/HBCR under the NCRP.
3. ICMR-NCDIR shall finalize datasets of each HBCR on an annual basis.
4. The individual C-PI is responsible for publication of the collected / verified data from the participating centre, after the data is accepted by ICMR-NCDIR, with due acknowledgement of ICMR-NCDIR-NCRP
5. It is encouraged that HBCRs should publish the data periodically in the form of annual reports/manuscripts with due acknowledgment of the ICMR-NCDIR and proper citation of the ICMR-NCDIR and HBCRDM software.
6. The analysis, report preparation and publication of the verified / collected pooled data is the responsibility of the ICMR-NCDIR-NCRP.
7. A list of papers published on the work carried out for this study by the HBCR under the auspices of the ICMR-NCDIR shall be submitted along with reprints of the papers periodically.
8. Data collected and finalized can be used for thesis/publication/sharing with government departments.

**J. Ethical Clearance:**

1. The participating centre shall obtain IEC approval for the project before commencement of data collection and submit the same to ICMR-NCDIR as per the ICMR 'National Ethical Guidelines for Biomedical and Health Research involving Human Participant-2017'. The necessary ethical clearance including patient consent will be the responsibility of the participating centre.



**K. Data Confidentiality:**

1. The participating centre will abide by the concerned ICMR-NCDIR policy on data processing and disclosure to ensure a stable, reliable, ethical and legally compliant framework for data collection, use and dissemination by the NCDIR.
2. The C-PI should ensure that the staff of the participating centre maintain patient confidentiality and also maintain data confidentiality and data security. Measures to maintain data security and protection as per the ICMR-NCDIR policy will be followed by the centre.

**L. Specific Conditions on Use of Software:**

1. No part of this software may be copied or used without the written consent of ICMR-NCDIR. Copyright © 2014, ICMR, New Delhi, All Rights Reserved.
2. Software, database and login credentials should be used only by authorized persons at authorized locations. Change of C-PI or discontinuation of the services of any hired manpower having knowledge of the login credentials must be intimated to ICMR-NCDIR so that the previous password is invalidated and fresh credentials will be issued to the participating centre. Undertaking on data confidentiality must be taken from staffs. Any violation of terms and conditions shall attract discontinuation of contract.

**M. Termination of the project:**

1. Either party can terminate the project, with valid reasons and adequate time.
2. A list (in duplicate) of non-expendable and expendable article together with property registers and suggestions for disposal of the articles should be sent to ICMR-NCDIR within a month from the date of termination of the research scheme.

*This MoU is valid for two calendar years and needs to be renewed by both parties.*

Certificate No.: JD(M)/HOTA/36/2022-23



## Government of Karnataka

Appropriate Authority for  
The Transplantation of Human Organs and Tissues Act, 1994  
Bangalore - 560 009.  
Form - 17

### CERTIFICATE OF RENEWAL REGISTRATION [Refer rule 25(2)]

This is with reference to application dated 10/09/2022 from 21/11/2022 to 20/11/2024  
KLES Dr.Prabhakar Kore Hospital & MRC, Nehru Nagar, Belagavi - 590010

(Name of the Hospital / Tissue Bank) for renewal of Certificate of Registration for performing organ (s) / tissue (s) retrieval / transplantation / banking under the Transplantation of Human Organs & Tissues Act, 1994 (42 of 1994).

After having considered the facilities and standards of the above - said hospital / tissue bank, the Appropriate Authority hereby renews the certificate of registration of the said hospital / tissue bank for a period of five years.

1. SKIN TRANSPLANTATION ..... 2. SKIN BANK .....

This renewal is being given with the current facilities and staff shown in the present application form. Any reduction in the staff and / or facility must be brought to the notice of the undersigned.

Place : Bengaluru

Date : 21/11/2022

\* Please see the conditions on the reverse

Chairman, Appropriate Authority

For the Transplantation of Human Organs & Tissues Act, 1994  
And, Commissioner, Health, Family Welfare and AYUSH Services



Certificate No.: JD(M)/HOTA/37/2021-22



## Government of Karnataka

Appropriate Authority for  
The Transplantation of Human Organs and Tissues Act, 1994  
Bangalore - 560 009.  
Form - 17

### CERTIFICATE OF RENEWAL REGISTRATION

[Refer rule 25(2)]

This is with reference to application dated 11-11-2021 from 22-03-2022 to 21-03-2027  
KLES Dr. Prabhakar Kore Hospital & MRC, Nehru Nagar, Belagavi - 590010

(Name of the Hospital / Tissue Bank) for renewal of Certificate of Registration for performing organ (s) / tissue (s) retrieval / transplantation / banking under the Transplantation of Human Organs & Tissues Act, 1994 (42 of 1994).

After having considered the facilities and standards of the above - said hospital / tissue bank, the Appropriate Authority hereby renews the certificate of registration of the said hospital / tissue bank for a period of five years.


1. KIDNEY TRANSPLANTATION 2. \_\_\_\_\_

This renewal is being given with the current facilities and staff shown in the present application form. Any reduction in the staff and / or facility must be brought to the notice of the undersigned.

Place: Bengaluru

Date: 22/03/2022

\* Please see the conditions on the reverse

  
Chairman, Appropriate Authority

For the Transplantation of Human Organs & Tissues Act, 1994  
And, Commissioner, Health, Family Welfare and AYUSH Services



## Annexure

No. JD(M)/HOTA/37/2021-22

Date: 24/03/2022

As per of KLES Dr.Prabhakar Kore Hospital & MRC,Nehru Nagar, Belagavi - 590010 request dated 11-11-2021 for issue the renewal registration to perform "Kidney Transplantation" is given for a period of 5 years from the date of issue of Certificate of registration. The said Hospital is permitted to conduct the above said organ transplantation surgeries with the following recognized team of Doctors.

### Kidney Transplantation Team :

#### Surgical Team:

1. Dr.R.B.Nerli
2. Dr.S.I.Neeli
3. Dr.Vikram Prabha
4. Dr.Shivagouda Patil

#### Medical Team:

1. Dr.M.S. Khanpet (Karishetti)
1. Dr.Ritesh Vernekar
2. Dr.Ravi Sarvi
3. Dr. Mahatesh Patil

#### Anesthesia Team :

1. Dr Rajesh Mane
2. Dr Vinay Jannu
3. Dr Guruprasad Shetty

#### ICU/ Critical Care Team:

1. Dr Manjunath Shivapujimath

**Transplant Co-ordinator :** 1. Mr.Neeraj Dixit  
2. Mrs.Parveen Y Pathan  
3. Mr.Rudra gouda Patil

If the team of Doctors changes, the Hospital authority has to inform the Appropriate Authority and take permission for the new team of doctors.

*PL*  
Commissioner

Health and Family Welfare Services &  
Chairman, Appropriate-Authority  
Transplantation of Human organs & Tissue Act, 1994



Certificate No.: JD(M)/HOTA/47/2022-23



## Government of Karnataka

Appropriate Authority for  
The Transplantation of Human Organs and Tissues Act, 1994  
Bangalore - 560 009.  
Form - 17

### CERTIFICATE OF RENEWAL REGISTRATION [Refer rule 25(2)]

This is with reference to application dated 07/12/2022 from 24/1/2023  
K.L.E'S DR. Prabhakar Kore Hospital & Medical Research centre, Nehru Nagar, Belagavi-590010

(Name of the Hospital / Tissue Bank) for renewal of Certificate of Registration for performing organ (s) / tissue (s) retrieval / transplantation / banking under the Transplantation of Human Organs & Tissues Act, 1994 (42 of 1994).

After having considered the facilities and standards of the above - said hospital / tissue bank, the Appropriate Authority hereby renews the certificate of registration of the said hospital / tissue bank for a period of ~~five years~~ two years

1. EYE BANK 2. KERATOPLASTY

This renewal is being given with the current facilities and staff shown in the present application form. Any reduction in the staff and / or facility must be brought to the notice of the undersigned.

Place : Bengaluru

Date : 24/01/2023

\* Please see the conditions on the reverse

  
24.01.2023  
Chairman, Appropriate Authority

For the Transplantation of Human Organs & Tissues Act, 1994  
And, Commissioner, Health, Family Welfare and AYUSH Services



Certificate No.: JD(M)/HOTA/33/2022-23



## Government of Karnataka

Appropriate Authority for  
The Transplantation of Human Organs and Tissues Act, 1994  
Bangalore - 560 009.  
Form - 17

### CERTIFICATE OF RENEWAL REGISTRATION [Refer rule 25(2)]

This is with reference to application dated ..... 27/07/2022 ..... from ..... 08/11/2022 ..... TO 07/11/2027 <sup>RLP</sup>  
KLEs Dr. Prabhakar Kore Hospital & Medical Research Centre, Nelugunagar, Belagavi - 590010  
(Name of the Hospital / Tissue Bank) for renewal of Certificate of Registration for performing organ (s) / tissue (s)  
retrieval / transplantation / banking under the Transplantation of Human Organs & Tissues Act, 1994 (42 of 1994).

After having considered the facilities and standards of the above - said hospital / tissue bank, the Appropriate Authority  
hereby renews the certificate of registration of the said hospital / tissue bank for a period of five years.

1. HEART HEART LUNG ..... 2. LUNG, CARDIAC HOMOGRAFT .....

This renewal is being given with the current facilities and staff shown in the present application form. Any reduction  
in the staff and / or facility must be brought to the notice of the undersigned.

Place : Bengaluru

Date : 8/11/2022

\* Please see the conditions on the reverse

  
Chairman, Appropriate Authority

For the Transplantation of Human Organs & Tissues Act, 1994  
And, Commissioner, Health, Family Welfare and AYUSH Services





Government of Karnataka  
Commissionerate of Health & Family Welfare Services,  
Arogya Soudha, Magadi Road, Bangalore-560 023.

No. JD(M)/HOTA/33/2022-23  
E -927681

Date: 9/11/2022

As per KLES Dr.Prabhakar Kore Hospital & MRC,Nehru Nagar, Belagavi - 590010 request dated :15-07-2022 for issue the renewal registration to perform "Heart, Heart-Lung, Lung and Cardiac Homograft" is renewed for the period of 2 years. The said Hospital is permitted to conduct "Heart, Heart-Lung, Lung and Cardiac Homograft Transplantation" with the following recognized team of Doctors

**Heart, Heart-Lung, Lung and Cardiac Homograft Transplantation Team :**

**Surgical Team:**

1. Dr. Richard Saldanha
2. Dr. Mohan Gan
3. Dr. Kiran Kurkure
4. Dr. Abhishek Prabhu
5. Dr. Darshan D.S
6. Dr. Tarun Raina Ramman
7. Dr. Parishwanath Patil MS

**Medical Team:**

1. Dr. Suresh V.Patted
2. Dr. Sanjay C. Porwal
3. Dr. Sameer Ambar
4. Dr. Prasad M.R
5. Dr. Vijay.B. Metgudmath
6. Dr,Vishwanath Hesrur
7. Dr.Suhasini Atharga
8. Dr. Veeresh Manvi
9. Dr.Danish Memon
10. Dr. Prabhu C. Halkati
11. Dr. Nidhi Goel Manvi

**Anesthesia Team :**

1. Dr. Anand Vagaralli
2. Dr. Sharangouda S Patil
3. Dr. Abhijit Shitole
4. Dr. Jabbar Momin
5. Dr. Shwethagouda Soorgonda

**Pulmonologist :**

1. Dr. Guruprasad Antin

**Transplant Co-ordinator :** 1. Mr. Pramod Sulikeri  
2. Mr. Vinayak Puranik  
3. Ms. Sangita Bhoi

If the team of doctors changes, the Hospital authority has to inform the Appropriate Authority and take permission for the new team of doctors. This annexure valid till 07.11.2024, within which Fire safety compliance report should be submitted failing which further renewal cannot be taken up.

  
Commissioner

Health and Family Welfare Services &  
Chairman, Appropriate Authority  
Transplantation of Human organs & Tissue Act, 1994



Certificate No.: JD(M)/HOTA/35/2022-23



## Government of Karnataka

Appropriate Authority for  
The Transplantation of Human Organs and Tissues Act, 1994  
Bangalore - 560 009.  
Form - 17

### CERTIFICATE OF RENEWAL REGISTRATION [Refer rule 25(2)]

This is with reference to application dated 30/09/2022 from 26/11/2022 TO 25/11/2024  
KLES Dr.Prabhakar Kore Hospital & Medical Research Centre, Nehru Nagar, Belagavi - 590010  
(Name of the Hospital / Tissue Bank) for renewal of Certificate of Registration for performing organ (s) / tissue (s)  
retrieval / transplantation / banking under the Transplantation of Human Organs & Tissues Act, 1994 (42 of 1994).

After having considered the facilities and standards of the above - said hospital / tissue bank, the Appropriate Authority hereby renews the certificate of registration of the said hospital / tissue bank for a period of five years.

1. LIVER TRANSPLANTATION 2. ....

This renewal is being given with the current facilities and staff shown in the present application form. Any reduction in the staff and / or facility must be brought to the notice of the undersigned.

Place : Bengaluru

Date : 21/11/2022

\* Please see the conditions on the reverse

  
Chairman, Appropriate Authority

For the Transplantation of Human Organs & Tissues Act, 1994  
And, Commissioner, Health, Family Welfare and AYUSH Services



# National Accreditation Board for Hospitals & Healthcare Providers

(Constituent Board of Quality Council of India)

## CERTIFICATE OF ACCREDITATION

**KLE Ayurveda Hospital & Medical Research Centre**

Shahapur  
Belagavi – 590003, Karnataka

has been assessed and found to comply with NABH accreditation standards for AYUSH Programmes. This certificate is valid for the Scope as specified in the annexure subject to continued compliance with the accreditation requirements.

Date of first Certification: July 03, 2016

Date of Previous Cycle  
July 03, 2019 to July 02, 2022

Valid from : July 03, 2022

Valid thru : July 02, 2025



Certificate No.  
AH-2016-0016

**Dr. Atul Mohan Kochhar**  
Chief Executive Officer

National Accreditation Board for Hospitals & Healthcare Providers, 5th Floor, ITPI Building, 4A, Ring Road, IP Estate, New Delhi 110 002, India  
Phone: +91-11-42600600, Fax: +91-11-2332 3415 • Email: helpdesk@nabh.co • Website: www.nabh.co



SI No. 014503



NABH as an organisation is ISQua Accredited





SI No. 014554



# National Accreditation Board for Hospitals & Healthcare Providers

(Constituent Board of Quality Council of India)

National Accreditation Board for Hospitals & Healthcare Providers  
5th Floor, ITPI Building, 4A, Ring Road, IP Estate, New Delhi 110 002, India  
Phone: +91-11-42600600, Fax: +91-11-2332 3415 • Email: helpdesk@nabh.co • Website: www.nabh.co

## SCOPE OF ACCREDITATION

**KLE Ayurveda Hospital  
& Medical Research Centre**  
Shahapur  
Belagavi – 590003, Karnataka

**Certificate No. AH-2016-0016**

Date of First Accreditation: July 03, 2016

Date of Previous Cycle  
July 03, 2019 to July 02, 2022

Valid from : July 03, 2022

Valid thru : July 02, 2025

### Scope of Services

- Kayachikitsa
- Panchakarma Treatments
- Shalya Tantra
- Shalakya Tantra
- Stree Roga evam Prasuti Tantra
- Kaumarabhritiya
- Damshttra Chikitsa
- Jara Chikitsa & Rasayana Chikitsa (including Vrisha Chikitsa)
- Manasaroga
- Swasthviritta & Yoga
- Rasashastra and Bhaishajya Kalpana
- Roga Nidana evam Vikriti Vigyan



NABH as an organisation is ISQua Accredited



**Dr. Atul Mohan Kochhar**  
Chief Executive Officer

# NATIONAL BOARD OF ACCREDITATION

NBCC Place, East Tower, 4<sup>th</sup> Floor, Bhasham Pitamah Marg,  
Pragati Vihar, New Delhi-110 003  
Tel: +91 11 2436 0620-22, 2436 0654 ; Telefax: +91 11 4308 4903  
Website: www.nbaind.org



Date: 03-02-2020

File No. 25-73-2010-NBA

To  
The Principal  
KLE College of Pharmacy,  
J.N. Medical College Campus,  
Nehru Nagar, Belgaum- 590010,  
Karnataka

Subject: Accreditation status of UG-Pharmacy program applied by KLE College of Pharmacy, J.N. Medical College Campus, Nehru Nagar, Belgaum- 590010, Karnataka.

Sir,

This has reference to your application I.D. No. 2962-05/06/2018 seeking accreditation by National Board of Accreditation to UG Pharmacy program offered by **KLE College of Pharmacy, J.N. Medical College Campus, Nehru Nagar, Belgaum- 590010, Karnataka.**

2. An Expert Team conducted on-site evaluation of the program from 08th to 09th November, 2019. The report submitted by the Expert Team was considered by the concerned Committees constituted for the purpose in NBA. The competent authority in NBA has approved the following accreditation status to the program as given in the table below:

Sl. No.	Name of the Program (UG)	Basis of Evaluation	Accreditation Status	Period of validity	Remarks
(1)	(2)	(3)	(4)	(5)	(6)
1.	Pharmacy	January 2016 Document	Accredited	Academic Years 2019-2020 to 2024-2025 i.e. upto 30-06-2025	Accreditation status granted is valid for the period indicated in Col.5 or till the program has the approval of the competent authority, whichever is earlier

3. It may be noted that only students who graduate during the validity period of accreditation, will be deemed to have graduated with an NBA accredited degree.

5. The accreditation status awarded to the program as indicated in the above table does not imply that the accreditation has been granted to **KLE College of Pharmacy, J.N. Medical College Campus, Nehru Nagar, Belgaum- 590010, Karnataka** as a whole. **As such the Institution should nowhere along with its name including on its letter head etc. write that it is accredited by NBA because it is program accreditation and not Institution accreditation. If such an instance comes to NBA's notice, this will be viewed seriously.** Complete name of the program accredited, level of program and the period of validity of accreditation, as well as the Academic Year from which the accreditation is effective should be mentioned unambiguously whenever and wherever it is required to indicate the status of accreditation by NBA.

6. The accreditation status of the above program is subject to change on periodic review, if needed by the NBA. It is desired that the relevant information in respect of accredited program as indicated in the table in paragraph 2, appears on the website and information bulletin of the Institute.

Contd/...



7. The accreditation status awarded to the program as indicated in table in paragraph 2 above is subject to maintenance of the current standards during the period of accreditation. If there are any changes in the status (major changes of faculty strength, organizational structure etc.), the same are required to be communicated to the NBA, with an appropriate explanatory note.

8. A copy each of the Report of Chairman of the Visiting Team and Evaluators' Report in respect of the above program is enclosed.

Yours faithfully,



(Dr. Anil Kumar Nassa)  
Member Secretary

**Encls:** 1. Copy of Report of Chairman of the Visiting Team.  
2. Copy of Expert Report of the Visiting Team.

**Copy to:**

1. The Registrar  
KLE Academy of Higher Education and Research,  
J.N. Medical College Campus,  
Nehru Nagar, Belgaum-590010 Karnataka
2. Director Technical Education  
Tantrik Shikshan Bhavan  
Palace Road,  
Bangalore- 560 001  
Karnataka
3. Master Accreditation Folder of the State
4. Accreditation File



# राष्ट्रीय प्रत्यायन बोर्ड

चौथा तल, ईस्ट टावर, एन. बी. सी. सी. प्लेस, भीष्म पितामह मार्ग, प्रगति विहार, लोधी रोड, नई दिल्ली -110003

## NATIONAL BOARD OF ACCREDITATION

4th Floor, East Tower, NBCC Place, Bhasham Pitamah Marg, Pragati Vihar, Lodhi Road, New Delhi 110003



File No. 25-78-2010-NBA

Date 06-10-2022

To,  
The Principal  
K.L.E Society's College of Pharmacy,  
Vidyanagar, Hubli-580031, Karnataka

**Subject: Further accreditation status on the basis of Compliance Report of UG-Pharmacy program offered by K.L.E Society's College of Pharmacy, Vidyanagar, Hubli-580031, Karnataka.**

Sir,

This is regarding Compliance Report submitted by **K.L.E Society's College of Pharmacy, Vidyanagar, Hubli-580031, Karnataka** for the UG-Pharmacy program which was accredited by NBA for Academic Years 2019-20 to 2021-22 whose validity of accreditation has expired on 30.06.2022.

2. An Expert Team conducted data verification of the program on 16<sup>th</sup> July, 2022. The report submitted by the Expert Team was considered by the concerned Committees constituted for the purpose in NBA. The Competent Authority in NBA has approved the following accreditation status to the program as given in the table below:

Sl. No.	Name of the Program (UG)	Basis of Evaluation	Accreditation Status	Period of validity	Remarks
(1)	(2)	(3)	(4)	(5)	(6)
1.	Pharmacy	January, 2016 Document	Accredited	Academic Years 2022-2023 to 2024-2025 i.e. Up to 30-06-2025	Accreditation status granted is valid for the period indicated in Col.5 or till the program has the approval of the Competent Authority, whichever is earlier

3. It may be noted that only students who graduate during the validity period of accreditation, will be deemed to have graduated with an NBA accredited degree.

4. The program has been granted accreditation for further 3 years. **K.L.E Society's College of Pharmacy, Vidyanagar, Hubli-580031, Karnataka** should submit fresh online application under SAR January, 2016 document through e-NBA portal at least five months before the expiry of validity of accreditation mentioned above.

5. The accreditation status awarded to the program as indicated in the above table does not imply that the accreditation has been granted to **K.L.E Society's College of Pharmacy, Vidyanagar, Hubli-580031, Karnataka** as a whole. **As such the Institution should nowhere along with its name including on its letter head etc. write that it is accredited by NBA because it is program accreditation and not Institution accreditation. If such an instance comes to NBA's notice, this will be viewed seriously.** Complete name of the program(s) accredited, level of program(s) and the period of validity of accreditation, as well as the Academic Year from which the accreditation is effective should be mentioned unambiguously whenever and wherever it is required to indicate the status of accreditation by NBA.

6. The accreditation status of the above program is subject to change on periodic review, if needed by the NBA. It is desired that the relevant information in respect of accredited program as indicated in the table in paragraph 2, appears on the website and information bulletin of the Institute.

Contd/..

7. The accreditation status awarded to the program as indicated in table in paragraph 2 above is subject to maintenance of the current standards during the period of accreditation. If there are any changes in the status (major changes of faculty strength, organizational structure etc.), the same are required to be communicated to the NBA, with an appropriate explanatory note.

8. A copy of Report of the Visiting Team in respect of the above program is enclosed.

Yours faithfully,



(Dr. Anil Kumar Nassa)  
Member Secretary

**Encls:** 1. Copy of Report of the Visiting Team in respect of the program.

**Copy to:**

1. The Registrar  
KLE Academy of Higher Education and Research  
J.N Medical College Campus  
Nehru Nagar, Belgaum-590010, Karnataka
2. Director Technical Education  
Tantrik Shikshan Bhawan  
Palace Road, Bangalore-560001, Karnataka
3. Accreditation File
4. Master Accreditation file of the State.



# राष्ट्रीय प्रत्यायन बोर्ड

चौथा तल, ईस्ट टावर, एन. बी. सी. सी. प्लेस, भीष्म पितामह मार्ग, प्रगति विहार, लोधी रोड, नई दिल्ली -110003  
**NATIONAL BOARD OF ACCREDITATION**  
4th Floor, East Tower, NBCC Place, Bhisham Pitamah Marg, Pragati Vihar, Lodhi Road, New Delhi 110003



F. No. 25-76-2010-NBA

Date: 07-07-2021

To,  
The Principal,  
K.L.E College of Pharmacy,  
2nd Block, Rajajinagar, Bangaluru, Karnataka – 560010.

Subject: Accreditation status of UG Pharmacy program applied by K.L.E College of Pharmacy 2nd Block, Rajajinagar, Bangaluru, Karnataka – 560010.

Sir,

This has reference to your application Id No. 4381-02/12/2019 seeking accreditation by National Board of Accreditation to the UG Pharmacy program offered by K.L.E College of Pharmacy 2nd Block, Rajajinagar, Bangaluru, Karnataka – 560010.

2. An Expert Team conducted onsite evaluation of the program from 20<sup>th</sup> to 21<sup>st</sup> March, 2021. The report submitted by the Expert Team was considered by the concerned Committees constituted for the purpose in NBA. The competent authority in NBA has approved the following accreditation status to the program as given in the table below:

Sl. No.	Name of the Program (UG)	Basis of Evaluation	Accreditation Status	Period of validity	Remarks
(1)	(2)	(3)	(4)	(5)	(6)
1.	Pharmacy	January, 2016 Document	Accredited	Academic Years 2021-2022 to 2026-2027 i.e. upto 30-06-2027	Accreditation status granted is valid for the period indicated in Col.5 or till the program has the approval of the competent authority, whichever is earlier.


3. It may be noted that only students who graduate during the validity period of accreditation, will be deemed to have graduated with an NBA accredited degree.

4. The accreditation status awarded to the program as indicated in the above table does not imply that the accreditation has been granted to K.L.E College of Pharmacy 2nd Block, Rajajinagar, Bangaluru, Karnataka – 560010 as a whole. As such the Institute should nowhere along with its name including on its letter head etc. write that it is accredited by NBA because it is program accreditation and not Institution accreditation. If such an instance comes to NBA's notice, this will be viewed seriously. Complete name of the program(s) accredited, level of program(s) and the period of validity of accreditation, as well as the date from which the accreditation is effective, should be mentioned unambiguously whenever and wherever it is required to indicate the status of accreditation by NBA.

Contd./-



5. The accreditation status of the above program is subject to change on periodic review, if needed by the NBA. It is desired that the relevant information in respect of accredited program as indicated in the Table in paragraph 2, appears on the website and information bulletin of your Institution.
6. The accreditation status of the above program is subject to change on periodic review, if needed by the NBA. It is desired that the relevant information in respect of accredited program as indicated in the Table in paragraph 2, appears on the website and information bulletin of your Institution.
7. The accreditation status awarded to the program as indicated in Table in paragraph 2 above is subject to maintenance of the current standards during the period of accreditation. If there are any changes in the status (major changes of faculty strength, organizational structure etc.), the same are required to be communicated to the NBA, with an appropriate explanatory note.
8. A copy each of Report of Chairman of the Visiting Team and Evaluators' report in respect of the above program is enclosed.

Yours faithfully,  
  
(Dr. Anil Kumar Nassa)  
Member Secretary

- Encls:** 1. Copy of Report of Chairman of the Visiting Team.  
2. Copy of Expert Report of the Visiting Team.
- Copy to:**

1. Department of Technical Education  
Tantrika Shikshana Bhavana, Palace Road,  
Bengaluru--560001.
2. The Registrar,  
K.L.E Academy of Higher Education and Research,  
JNMC Campus, Nehru Nagar  
Belgaum-590010, Karnataka
3. Accreditation File
4. Master Accreditation file of the State



सत्यमेव जयते

**Government of India  
Ministry of Health & Family Welfare  
Department of Health Research**

2nd Floor, IRCS Building,  
New Delhi - 110001  
Dated : 14-Jun-2023

**Provisional Certificate**

**Subject: Provisional registration of the Ethics Committee relating to Biomedical and Health Research with the National Ethics Committee Registry for Biomedical and Health Research (NECRBHR), Department of Health Research (DHR).**

In exercise of the powers conferred by sub-rule (3) of rule 17 of the New Drugs and Clinical Trials Rules, 2019, the designated authority in the Department of Health Research, Ministry of Health & Family Welfare, hereby provisionally registers and permits the following Ethics Committee to perform the duties of ethics committee as specified in Chapter-IV of the New Drugs and Clinical Trials Rules, 2019.

**Name :** klecopbgm ethics committee  
**Address :** KLE College of Pharmacy, JNMC Campus Nehru Nagar, Belgavi, Belgavi (Belgaum), Karnataka - 590010  
**Contact No:** 08321247400  
**Fax :** 08321247400

2. The Ethics Committee shall observe all the conditions as stipulated in Chapter-IV of the aforesaid Rules, i.e., New Drugs and Clinical Trials Rules, 2019 and the National Ethical Guidelines for Biomedical and Health Research Involving Human Participants, specified by the Indian Council of Medical Research (ICMR).

3. The designated authority shall scrutinize the documents and information furnished with the application by the Ethics Committee for the issue of final registration certificate.

4. The above provisional registration shall be valid for a maximum period of two years from the date of its issue or till grant of final registration or rejection of provisional registration, whichever is earlier.

Note: EC registration number provided by DHR should be displayed on every certificate of approval issued by the Ethics committee

(Anu Nagar)  
Joint Secretary  
Department of Health Research  
Designated Authority



A constituent Unit of  
KLE Academy of Higher Education and Research  
(Deemed-to-be-University)

Accredited 'A+' Grade by NAAC (3<sup>rd</sup> Cycle) Placed in Category 'A' by MoE [MHRD] (GoI)

**NEHRU NAGAR, BELAGAVI-590010, KARNATAKA, INDIA**

☎: 091-0831-2472303

FAX: 091- 0831-2475103

Web: <http://kleunursingbgm.edu.in>

E-


mail: [principalklenursingbgv@gmail.com](mailto:principalklenursingbgv@gmail.com)

Recognized by: Indian Nursing Council (New Delhi)-Karnataka Nursing Council (Bengaluru, Karnataka)


### 3. VIRTUAL SIGNING OF MEMORANDUM OF UNDERSTANDING (MOU)

KAHER INS Signed MoU with Southern Cross University, Australia with the purpose of cooperative academic relationship between two institutions on 25<sup>th</sup> July 2023

The proposed program for 20 (max) undergraduate nursing students to participate in offshore nursing placements (KAHER) is designed to develop student's ability to use partnership techniques to work with individuals, groups, families and vulnerable populations to address healthcare and social inequities and build healthy communities to promote and improve wellbeing.



4. The Institute also has an active MoU with Southern Cross University Australia. The New Colombo Plan (NCP) is a signature initiative of the Australian Government offering Australian undergraduate's prestigious scholarships and grants for the opportunity to study and undertake internships/mentorships in India. As a part of MoU there is an e-learning program developed known as Practera App on Student Nurses Leadership and Communication skills in chronic diseases management and delivery of primary health care.



03 Midwifery Students from East Anglia University Norwich United Kingdom visited KAHER INS Belagavi from 10.07.2023 to 22.07.2023 under student exchange program.







A constituent Unit of  
KLE Academy of Higher Education and Research  
(Deemed-to-be-University)

Accredited 'A+' Grade by NAAC (3<sup>rd</sup> Cycle) Placed in Category 'A' by MoE [MHRD] (GoI)

**NEHRU NAGAR, BELAGAVI-590010, KARNATAKA, INDIA**

☎: 091-0831-2472303

FAX: 091- 0831-2475103

Web: <http://kleunursingbgm.edu.in>

E-


mail: [principalklenursingbgv@gmail.com](mailto:principalklenursingbgv@gmail.com)

Recognized by: Indian Nursing Council (New Delhi)-Karnataka Nursing Council (Bengaluru, Karnataka)


### 3. VIRTUAL SIGNING OF MEMORANDUM OF UNDERSTANDING (MOU)

KAHER INS Signed MoU with Southern Cross University, Australia with the purpose of cooperative academic relationship between two institutions on 25<sup>th</sup> July 2023

The proposed program for 20 (max) undergraduate nursing students to participate in offshore nursing placements (KAHER) is designed to develop student's ability to use partnership techniques to work with individuals, groups, families and vulnerable populations to address healthcare and social inequities and build healthy communities to promote and improve wellbeing.



4. The Institute also has an active MoU with Southern Cross University Australia. The New Colombo Plan (NCP) is a signature initiative of the Australian Government offering Australian undergraduate's prestigious scholarships and grants for the opportunity to study and undertake internships/mentorships in India. As a part of MoU there is an e-learning program developed known as Practera App on Student Nurses Leadership and Communication skills in chronic diseases management and delivery of primary health care.



03 Midwifery Students from East Anglia University Norwich United Kingdom visited KAHER INS Belagavi from 10.07.2023 to 22.07.2023 under student exchange program.





# INSTITUTE OF NURSING SCIENCE



A constituent Unit of  
KLE Academy of Higher Education and Research  
(Deemed-to-be-University)

Accredited 'A+' Grade by NAAC (3<sup>rd</sup> Cycle) Placed in Category 'A' by MoE [MHRD] (GoI)

NEHRU NAGAR, BELAGAVI-590010, KARNATAKA, INDIA

☎: 091-0831-2472303

FAX: 091- 0831-2475103

Web: <http://kleunursingbgm.edu.in>

E-

mail: [principalkleunursingbgv@gmail.com](mailto:principalkleunursingbgv@gmail.com)



Recognized by: Indian Nursing Council (New Delhi)-Karnataka Nursing Council (Bengaluru, Karnataka)



## Employment & Language Skill Development Program.

Institute has MoU with German Aspiration for the implementation of Employability and Language skill development scheme. At present 25 students of B.Sc & 29 students of GNM have cleared the A-2 German Language phase. 22 students got selected and are ready to fly to Germany.

- Institute is also in the process of MoU with Ajinorah Institutions for OET/ IELTS training programs.



*[Handwritten Signature]*  
Principal  
KAHER INS  
Belagavi





सत्यमेव जयते

INDIA NON JUDICIAL



**Government of Karnataka**

Rs. 100

**e-Stamp**

**Certificate No.** : IN-KA36710369210485U  
**Certificate Issued Date** : 14-Feb-2022 12:24 PM  
**Account Reference** : SHCIL (FI)/ ka-shcil/ SHCIL BELGAUM/ KA-BL  
**Unique Doc. Reference** : SUBIN-KAKA-SHCIL12242682100436U  
**Purchased by** : REGISTRAR KAHER  
**Description of Document** : Article 12 Bond  
**Description** : M O U  
**Consideration Price (Rs.)** : 0  
 (Zero)  
**First Party** : REGISTRAR KAHER  
**Second Party** : GERMAN ASPIRATION  
**Stamp Duty Paid By** : REGISTRAR KAHER  
**Stamp Duty Amount(Rs.)** : 100  
 (One Hundred only)

सत्यमेव जयते



Please write or type below this line

**MEMORANDUM OF UNDERSTANDING**

This Memorandum of Understanding is made and executed on this the 14<sup>th</sup> Day of February 2022 (effective date)

...2

*Kaher*

REGISTRAR

KLE Academy of Higher Education  
and Research, BELAGAVI

*Vand M*

**Statutory Alert:**

1. The authenticity of this Stamp certificate should be verified at 'www.shcilestamp.com' or using e-Stamp Mobile App of Stock Holding. Any discrepancy in the details on this Certificate and as available on the website / Mobile App renders it invalid.
2. The onus of checking the legitimacy is on the users of the certificate.
3. In case of any discrepancy please inform the Competent Authority



BETWEEN

GERMAN ASPIRATION  
 Represented by its Proprietor  
 Mr. Veeresh Awaknavar  
 R/o Verma Suite # 302, Datta Krupa Sankul,  
 Shukrawar Peth, Tilakwadi, Belgaum Karnataka

(which expression shall mean and include his legal representatives, heirs, assigns, administrators etc) On the ONE PART

AND


KLE Academy of Higher Education & Research  
 A deemed to be university established u/s 3 of the UGC Act, 1956  
 For its KAHER Institute of Nursing  
 Represented by the Registrar  
 Prof. Dr. V. A Kothiwale  
 Nehru Nagar, Belagavi, Karnataka, India  
 (Hereinafter referred to as 'KAHER' on the OTHER PART


About GERMAN ASPIRATION

German Aspiration is a professionally managed career scouting service representing and promoting world leaders in skill development, WBS Training which is supported by the Government of Germany, Ministry of Education. German Aspiration does handholding of candidates all the way from skill development to completing vocational training programs in Germany and ultimately beginning their professional journey in Germany.

*Pioneers in Training*

We offer precise training methods for you, which means assured international standard training. The skill development programs allow you to work seamlessly in leading German environments.

  
 REGISTRAR  
 KLE Academy of Higher Education  
 and Research, BELAGAVI





## About KAHER


KAHER is a deemed to be University consisting of 9 constituent units. The Institute of Nursing Sciences was established in May 1987 and recognized as one of the top institution in India. All the courses offered by institution are recognized by apex bodies like Indian Nursing Council, Karnataka Nursing Council and Govt. of Karnataka. The institution attached to own parent hospital i.e. KLES Dr.Prabhakar Kore Hospital & MRC with 2400 bed strength and 256 ICU beds accredited with NABH safe 'I' & NABL accredited laboratories, KLES Belgaum Cancer Hospital & KLES Centenary Charitable Hospital.


### Scope of understanding

WHEREAS German Aspiration is the leading training implementation for the jobs internationally at Germany, Canada and UK and second party KLE Academy of higher education and research is the ...best University to train the candidates to fulfill the requirement at workplace. Both parties are agreed with mutual consent.

### Obligations of cooperating associates

WHEREAS German aspiration shall impart training on German Language to the students, faculty and alumni of KAHER Institute of Nursing. KAHER shall provide the space for the German Aspiration to conduct the courses. The mode of conducting classes i.e online/offline, shall be decided on the basis of registrations. It shall be an 8 months training and Certification Course named as German Language Certification Course. The highly skilled trainers both from India as well as Germany shall train the candidates in 4 levels of Learning i.e A1, A2. B1 and B2.

  
REGISTRAR  
KLE Academy of Higher Education  
and Research, BELAGAVI





4  
WHEREAS the course material shall be provided by German Aspiration. KAHER has to facilitate registration of students. The course content shall be Language training along with cultural interaction.

WHEREAS German Aspiration shall simultaneously assist in Visa Processing and Placement for the candidates internationally. German Aspiration shall also assist the candidates in getting scholarship and stipend during the course or during the initial period of placement.

#### Financials


No financial transaction shall take place between the both of parties. Each party shall bear the expenses incurred by them.


#### Premises

KAHER shall facilitate the training programme at its own premises at KAHER Institute of Nursing. All facilities e.g. machine, electricity, gadgets, drinking water, wash room, Internet for online instructions from German Trainers.

#### Term and Renewal

This Contract shall remain in force for the period of 3 years mutually agreed from the date of signature, with the understanding that either party may terminate it in any year by giving written 3 months prior written notice to the other party. The agreement may be extended by mutual consent of the two parties. The contract may be amended by written agreement signed by the authorized persons at each institution.

  
REGISTRAR  
KLE Academy of Higher Education  
and Research, BELAGAVI





### Termination

In case of the termination of such Job Training Contract/ Placement contract will be valid up to the last German Aspiration candidate of the cooperating associate. This contract will be automatically be terminated if second party is found or gets into to alliance with any other service provider where the interest of first party are conflicted or is in competition with the first party.


### Governing Law

For all disputes and misunderstandings first step would be an out of the court amicable measures which will be effectively taken and practiced that also includes arbitration.

However if in any case need arises then this declaration shall be governed by the laws of the state of India, jurisdiction will be Belagavi, Karnataka. This choice of law, venue, and jurisdiction provision is not permissive but rather mandatory in nature.


In WITNESS WHEREOFF the parties have put their signature to this MOU on the day and date mentioned above.

KLE ACADEMY OF HIGHER  
EDUCATION AND RESEARCH




Dr. V. A Kothiwale  
Registrar

GERMAN ASPIRATION



Mr. Veeresh Awaknavar  
Proprietor

Witnesses

1. Sudha [DR. SUDHA A RADD]
2. Vinayak Naik - 





**GERMAN  
ASPIRATION**

Count on us to build your dream life

GSTIN: 29ALAPA4953F1ZC  
Contact: +91 7022 393 639  
www.germanaspiration.in  
germanaspiration@gmail.com

This is to inform you that, candidates from KAHER INSTITUTE OF NURSING SCIENCES NEHRU NAGAR, BELAGAVI, got placed in Klinikum Bremer Heven Germany. I congratulate candidates and also thank the institution for their kind support.

Here are the list of candidates who got selected.

1. Aiyukta Anand Gawas
2. Archana Sawmyakumar
3. Ashwini Shivagouda Patil
4. Dimple Sharma
5. Dipti dilip Shetkar
6. Franola Coehlo
7. Heenakousur Jamadar
8. Jashwel Moterio
9. Jyoti Ghadi
10. Lareina Romeena Coutinho
11. Megha Suresh Acharya
12. Muriel Pearl Mendes
13. Muskan Shaikh
14. Princy Mena Colaco
15. Saloni Talwanekar
16. Sangeeta Shivappa Ghodageri
17. Suja Kanichattu Vijayan
18. Swapna Shivappa Ghodageri
19. Uma Pratap Rathod

KAHER INSTITUTE OF NURSING SCIENCES  
NEHRU NAGAR, BELAGAVI - 590010

DATE 08/01/2023

FORWARD NO. \_\_\_\_\_



Your's Faithfully  
For GERMAN ASPIRATION

8/01/24.  
Authorised Signatory



Ministry of  
Education  
Government of India



MoE's  
INNOVATION CELL  
(GOVERNMENT OF INDIA)



INSTITUTION'S  
INNOVATION  
COUNCIL  
(Ministry of Education Initiative)



## CERTIFICATE

Institution's Innovation Council (IIC) established at

**KLE College of Pharmacy, Bangalore, Bengaluru Urban**

had undertaken various activities prescribed by Innovation Cell, Ministry of Education, Govt. of India to promote Innovation and Start-up in campus during the IIC calendar year 2022-23.

**Prof. TG Sitharam**  
Chairman  
Aicte

**Dr. Abhay Jere**  
Chief Innovation Officer  
MOE, Innovation Cell

**Mr. Dipan Sahu**  
Assistant Innovation Director  
MOE, Innovation Cell

Certificate No : 7542

Issued On : 2023-11-16



## Letter of Appreciation

Dear Sir/Madam,

Please accept our sincere gratitude to all the chief functionaries and every members of the IIC Institution's Innovation Council (IIC) of KLE College of Pharmacy, Bangalore for the continuous support and contribution towards building the innovation and entrepreneurship culture development in your campus and also extending support to help other IIC institutions towards growth of the IIC network during the academic year 2022-23.

Chief Functionaries of the IIC at KLE College of Pharmacy, Bangalore, Bengaluru Urban

Name	Position
Dr. Rajamma A J	President
Ms. Priyanka Tiwari	Innovation Activity, Member
Dr. Mamatha A	Vice President, Member
Mrs. Dimple Pirgal	Convener, Member
Dr. Anusuya Patil	Start up Activity Coordinator, NIRF Coordinator
Dr. P V Murali Krishna	Internship Activity Coordinator, Member
Dr. Subhas S Karki	IPR Activity Coordinator, Member
Mr. Akshay Kumar K S	Social Media, ARIIA Coordinator

As we are progressing towards a 'quality' driven I&E ecosystem development, we strongly believe that the IIC model and its unique structure is definitely putting your HEI's thoughts, actions and aspirations in a systematic way to achieve inclusive and holistic development of the ecosystem.

Thanks & regards.

Yours Sincerely,

Dipan Kumar Sahu



Assistant Innovation Director  
MoE's Innovation Cell, Govt. of India



Ministry of Education  
Government of India



# Certificate

**NATIONAL INSTITUTIONAL RANKING FRAMEWORK**

**INDIA RANKINGS 2023**

**KLE Vishwanath Katti Institute of Dental Sciences Belgaum  
Ranked 35 in Dental Category**

CHAIRMAN, NBA

MEMBER SECRETARY, NBA





Ministry of Education  
Government of India



# Certificate

**NATIONAL INSTITUTIONAL RANKING FRAMEWORK**

**INDIA RANKINGS 2023**

**KLE College of Pharmacy, Belgaum  
Ranked 39 in Pharmacy Category**

CHAIRMAN, NBA

MEMBER SECRETARY, NBA



Ministry of  
Education  
Government of India



MoE's  
INNOVATION CELL  
(GOVERNMENT OF INDIA)



INSTITUTION'S  
INNOVATION  
COUNCIL  
(Ministry of Education Initiative)



## CERTIFICATE

Institution's Innovation Council (IIC) established at

**KLE Institute of Physiotherapy, Belagavi**

had undertaken various activities prescribed by Innovation Cell, Ministry of Education, Govt. of India to promote Innovation and Start-up in campus during the IIC calendar year 2022-23.

**Prof. TG Sitharam**  
Chairman  
Aicte

**Dr. Abhay Jere**  
Chief Innovation Officer  
MOE, Innovation Cell

**Mr. Dipan Sahu**  
Assistant Innovation Director  
MOE, Innovation Cell

Certificate No : 7890

Issued On : 2023-11-16





Ministry of  
Education  
Government of India



MoE's  
INNOVATION CELL  
(GOVERNMENT OF INDIA)



INSTITUTION'S  
INNOVATION  
COUNCIL  
(Ministry of Education Initiative)



## CERTIFICATE

Institution's Innovation Council (IIC) established at

**K.L.E. Academy of Higher Education and Research, Belagavi**

had undertaken various activities prescribed by Innovation Cell, Ministry of Education, Govt. of India to promote Innovation and Start-up in campus during the IIC calendar year 2022-23.

**Prof. TG Sitharam**  
Chairman  
Aicte

**Dr. Abhay Jere**  
Chief Innovation Officer  
MOE, Innovation Cell

**Mr. Dipan Sahu**  
Assistant Innovation Director  
MOE, Innovation Cell

Certificate No : 11327

Issued On : 2023-11-16



Ministry of  
Education  
Government of India



MoE's  
INNOVATION CELL  
(GOVERNMENT OF INDIA)



INSTITUTION'S  
INNOVATION  
COUNCIL  
(MINISTRY OF EDUCATION, GOVERNMENT OF INDIA)



## CERTIFICATE OF ESTABLISHMENT

This is to certify that

**K.L.E. Academy of Higher Education and Research, Belagavi**

has established an Institution's Innovation Council (IC202221783) in the campus as per the norms of Innovation Cell, Ministry of Education, Govt. of India during the academic calendar year 2022-23

Prof. Anil D. Sahasrabudhe  
Chairman  
AICTE

Dr. Abhay Jere  
Chief Innovation Officer  
Ministry of Education's Innovation Cell

Certificate No: 11327

Aishe Code: U-0225

Date: 20-10-2022